

# 1 **A genetically encoded fluorescent sensor for rapid and** 2 **specific *in vivo* detection of norepinephrine**

3  
4 Jiesi Feng<sup>1,2,3</sup>, Changmei Zhang<sup>4,8</sup>, Julieta Lischinsky<sup>5,9,10</sup>, Miao Jing<sup>1,2,3</sup>, Jingheng Zhou<sup>6</sup>,  
5 Huan Wang<sup>1,2</sup>, Yajun Zhang<sup>1,3,7</sup>, Ao Dong<sup>1,2,3</sup>, Zhaofa Wu<sup>1,2</sup>, Hao Wu<sup>1,2,12</sup>, Weiyu Chen<sup>4,8</sup>,  
6 Peng Zhang<sup>7</sup>, Jing Zou<sup>11</sup>, S. Andrew Hires<sup>11</sup>, J. Julius Zhu<sup>7,13,14,15</sup>, Guohong Cui<sup>6</sup>, Dayu  
7 Lin<sup>5,9,10</sup>, Jiulin Du<sup>4,8</sup>, Yulong Li<sup>1,2,3,16,\*</sup>

8  
9 <sup>1</sup>State Key Laboratory of Membrane Biology, Peking University School of Life Sciences,  
10 Beijing 100871, China

11 <sup>2</sup>PKU-IDG/McGovern Institute for Brain Research, Beijing 100871, China

12 <sup>3</sup>Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary  
13 Studies, Peking University, Beijing 100871, China

14 <sup>4</sup>Institute of Neuroscience, State Key Laboratory of Neuroscience, CAS Center for  
15 Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences,  
16 Shanghai 200031, China

17 <sup>5</sup>Neuroscience Institute, New York University School of Medicine, New York, NY 10016,  
18 USA

19 <sup>6</sup>Neurobiology Laboratory, National Institute of Environmental Health Sciences, National  
20 Institutes of Health, Research Triangle Park, NC 27709, USA

21 <sup>7</sup>Department of Pharmacology, University of Virginia School of Medicine, Charlottesville,  
22 VA 22908, USA

23 <sup>8</sup>University of Chinese Academy of Sciences, Beijing 100049, China

24 <sup>9</sup>Department of Psychiatry, New York University School of Medicine, New York, NY 10016,  
25 USA

26 <sup>10</sup>Center for Neural Science, New York University, New York, NY 10016, USA

27 <sup>11</sup>Department of Biological Sciences, Neurobiology Section, University of Southern  
28 California, Los Angeles, CA 90089, USA

29 <sup>12</sup>School of Life Sciences, Tsinghua University, Beijing 100084, China

30 <sup>13</sup>School of Medicine, Ningbo University, Ningbo, 315010, China

31 <sup>14</sup>Donders Institute for Brain, Cognition and Behavior, Radboud University Nijmegen, 6525

32 EN, Nijmegen, Netherlands

33 <sup>15</sup>Department of Physiology, School of Basic Medicine, Tongji Medical College, Huazhong  
34 University of Science and Technology, Wuhan 430030, China

35 <sup>16</sup>Lead contact

36

37 \*Manuscript correspondence:

38 Yulong Li (yulongli@pku.edu.cn)

39

#### 40 **Acknowledgements**

41 This work was supported by the National Basic Research Program of China (973 Program;  
42 grant 2015CB856402), the General Program of National Natural Science Foundation of  
43 China (project 31671118), the NIH BRAIN Initiative grant U01NS103558, the Junior  
44 Thousand Talents Program of China, the grants from the Peking-Tsinghua Center for Life  
45 Sciences, and the State Key Laboratory of Membrane Biology at Peking University School  
46 of Life Sciences to Y. L.; the Key Research Program of Frontier Sciences (QYZDY-SSW-  
47 SMC028) of Chinese Academy of Sciences, and Shanghai Science and Technology  
48 Committee (18JC1410100) to J.D.; the NIH grants R01MH101377 and R21HD090563 and  
49 an Irma T. Hirschl Career Scientist Award to D.L.; and the Intramural Research Program of  
50 the NIH/NIEHS of the United States (1ZIAES103310) to G.C.

51 We thank Yi Rao for sharing the two-photon microscope and Xiaoguang Lei for the platform  
52 support of the Opera Phenix high-content screening system at PKU-CLS. We thank the  
53 Core Facilities at the School of Life Sciences, Peking University for technical assistance.  
54 We thank Bryan L. Roth and Nevin A. Lambert for sharing stable cell lines and plasmids.  
55 We thank Yue Sun, Sunlei Pan, Lun Yang, Haohong Li for inputs on sensors'  
56 characterization and application. We thank Yanhua Huang, Liqun Luo and Mickey London  
57 for valuable feedback of the manuscript.

58

#### 59 **Author Contributions**

60 Y. L conceived and supervised the project. J.F., M.J., H.Wang, A.D., and Z.W. performed  
61 experiments related to sensor development, optimization, and characterization in culture  
62 HEK cells, culture neurons and brain slices. Y.Z., P.Z. and J.J.Z designed and performed  
63 experiments using Sindbis virus in slices. C.Z., W.C., and J.D. designed and performed  
64 experiments on transgenic fish. J.L., J.Zhou, H.Wu, J.,Zou, S.A.H., G.C., and D.L.  
65 designed and performed experiments in behaving mice. All authors contributed to data  
66 interpretation and data analysis. Y. L and J.F. wrote the manuscript with input from M.J.,

67 J.L., and D.L. and help from other authors.

68

69 **Declaration of Interests**

70 The authors declare competing financial interests. J.F., M.J., H.Wang, and Y. L have filed  
71 patent applications whose value might be affected by this publication.

72

73 **Abstract**

74 Norepinephrine (NE) and epinephrine (Epi), two key biogenic monoamine  
75 neurotransmitters, are involved in a wide range of physiological processes. However, their  
76 precise dynamics and regulation remain poorly characterized, in part due to limitations of  
77 available techniques for measuring these molecules *in vivo*. Here, we developed a family  
78 of GPCR Activation-Based NE/Epi (GRAB<sub>NE</sub>) sensors with a 230% peak  $\Delta F/F_0$  response  
79 to NE, good photostability, nanomolar-to-micromolar sensitivities, sub-second rapid  
80 kinetics, high specificity to NE vs. dopamine. Viral- or transgenic- mediated expression of  
81 GRAB<sub>NE</sub> sensors were able to detect electrical-stimulation evoked NE release in the locus  
82 coeruleus (LC) of mouse brain slices, looming-evoked NE release in the midbrain of live  
83 zebrafish, as well as optogenetically and behaviorally triggered NE release in the LC and  
84 hypothalamus of freely moving mice. Thus, GRAB<sub>NE</sub> sensors are a robust tool for rapid and  
85 specific monitoring of *in vivo* NE/Epi transmission in both physiological and pathological  
86 processes.

87

## 88 Introduction

89 Both norepinephrine (NE) and epinephrine (Epi) are key monoamine neurotransmitters in  
90 the central nervous systems and peripheral organs of vertebrate organisms. These  
91 transmitters play an important role in a plethora of physiological processes, allowing the  
92 organism to cope with its ever-changing internal and external environment. In the brain,  
93 NE is synthesized primarily in the locus coeruleus (LC), a small yet powerful nucleus  
94 located in the pons. Noradrenergic LC neurons project throughout the brain and exert a  
95 wide range of effects, including processing sensory information (Berridge and Waterhouse,  
96 2003), regulating the sleep-wake/arousal state (Berridge et al., 2012), and mediating  
97 attentional function (Bast et al., 2018). Blocking noradrenergic transmission causes  
98 impaired cognition and arousal and is closely correlated with a variety of psychiatric  
99 conditions and neurodegenerative diseases, including stress (Chrousos, 2009), anxiety  
100 (Goddard et al., 2010), depression (Moret and Briley, 2011), attention-deficit hyperactivity  
101 disorder (ADHD) (Berridge and Spencer, 2016), and Parkinson's disease (PD) (Espay et  
102 al., 2014). In the sympathetic nervous system, both NE and Epi play a role in regulating  
103 heart function (Brodde et al., 2001) and blood pressure (Zimmerman, 1981).

104 Despite their clear importance in a wide range of physiological processes, the spatial and  
105 temporal dynamics of NE and Epi in complex organs (e.g. the vertebrate brain) are poorly  
106 understood at the *in vivo* level due to limitations associated with current detection methods.  
107 Classic detection methods such as microdialysis-coupled biochemical analysis (Bito et al.,  
108 1966; Justice, 1993; Watson et al., 2006) have low temporal resolution, requiring a  
109 relatively long time (typically 5 min/collection) and complex sampling procedures, thereby  
110 limiting the ability to accurately measure the dynamics of noradrenergic activity in the  
111 physiological state (Chefer et al., 2009). Recent improvements in microdialysis—in  
112 particular, the introduction of the nano-LC-microdialysis method (Lee et al., 2008; Olive et  
113 al., 2000)—have significantly increased detection sensitivity; however, this approach is still  
114 limited by a relatively slow sampling rate (on the order of several minutes). On the other  
115 hand, electrochemical detection techniques based on measuring currents generated by  
116 the oxidation of NE/Epi (Bruns, 2004; Park et al., 2009; Robinson et al., 2008; Zhou and  
117 Mislser, 1995) provide nanomolar sensitivity and millisecond temporal resolution; however,  
118 their inability to distinguish NE and Epi from other monoamine neurotransmitters—  
119 particularly dopamine (Robinson et al., 2003)—presents a significant physiological  
120 limitation with respect to measuring noradrenergic/adrenergic transmission both in *ex vivo*  
121 tissue preparations and *in vivo*. In addition, both microdialysis-based and electrochemical  
122 techniques are designed to detect volume-averaged NE/Epi levels in the extracellular fluid  
123 and therefore cannot provide cell type-specific or subcellular information.

124 Real-time imaging of NE dynamics would provide an ideal means to non-invasively track  
125 NE with high spatiotemporal resolution. A recent innovation in real-time imaging, the cell-  
126 based reporters known as CNiFERs (Muller et al., 2014), converts an extracellular NE  
127 signal into an intracellular calcium signal that can be measured using highly sensitive

128 fluorescence imaging. However, CNiFERS require implantation of exogenous cells and can  
129 report only volume transmission of NE/Epi. By contrast, genetically encoded sensors, in  
130 theory, circumvent the above-mentioned limitations to provide fast, clear, non-invasive, cell  
131 type-specific reporting of NE/Epi dynamics. In practice, all genetically encoded NE sensors  
132 developed to date have poor signal-to-noise ratio and narrow dynamic range (e.g., a <10%  
133 change in FRET ratio under optimal conditions) (Nakanishi et al., 2006; Vilardaga et al.,  
134 2003; Wang et al., 2018b), thus limiting their applicability, particularly in *in vivo* applications.

135 To overcome these limitations, we developed a series of genetically encoded single-  
136 wavelength fluorescent GRAB<sub>NE</sub> sensors with rapid kinetics, a  $\Delta F/F_0$  dynamic range of  
137 ~200%, and EGFP-comparable spectra, brightness, and photostability. Here, we  
138 showcase the wide applicability of our GRAB<sub>NE</sub> sensors using a number of *in vitro* and *in*  
139 *vivo* preparations. In every application tested, the GRAB<sub>NE</sub> sensors readily reported robust,  
140 chemical-specific NE signals. Thus, our GRAB<sub>NE</sub> sensors provide a powerful imaging-  
141 based probe for measuring the cell-specific regulation of adrenergic/noradrenergic  
142 transmission under a wide range of physiological and pathological conditions.

143

## 144 **Results**

### 145 ***Development and characterization of GRAB<sub>NE</sub> sensors***

146 Inspired by the structure (Rasmussen et al., 2011a; Rasmussen et al., 2011b) and working  
147 mechanism (Chung et al., 2011; Manglik et al., 2015; Nygaard et al., 2013) of the  $\beta$ 2  
148 adrenergic G protein–coupled receptor (GPCR), we exploited the conformational change  
149 between the fifth and sixth transmembrane domains (TM5 and TM6, respectively) upon  
150 ligand binding to modulate the brightness of an attached fluorescent protein. Building upon  
151 the successful strategy of generating GPCR activation-based sensors for acetylcholine  
152 (GACH) (Jing et al., 2018) and dopamine (GRAB<sub>DA</sub>) (Sun et al., 2018), we first  
153 systematically screened human adrenergic receptors as a possible scaffold. We inserted  
154 circularly permuted EGFP (cpEGFP) into the third intracellular loop domain (ICL3) of three  
155  $\alpha$ -adrenergic receptors ( $\alpha$ 1DR,  $\alpha$ 2AR, and  $\alpha$ 2BR) and two  $\beta$ -adrenergic receptors ( $\beta$ 2R  
156 and  $\beta$ 3R) (Fig. 1A). Among these five constructs, we found that  $\alpha$ 2AR-cpEGFP had the  
157 best membrane trafficking, indicated by its high colocalization with membrane-targeted  
158 RFP (Fig. S1); we therefore selected this construct as the scaffold for further screening.

159 The length of the linker surrounding the cpEGFP moiety inserted in G-GECO (Zhao et al.,  
160 2011), GCaMP (Akerboom et al., 2012), GACH (Jing et al., 2018), and GRAB<sub>DA</sub> (Sun et al.,  
161 2018) can affect the fluorescence response of cpEGFP-based indicators. Thus, as the next  
162 step, we systematically truncated the linker which starts with the entire flexible ICL3 of  
163  $\alpha$ 2AR surrounding cpEGFP (Fig. 1B). We initially screened 275 linker-length variant  
164 proteins and identified a sensor (GRAB<sub>NE0.5m</sub>) with a modest response to NE (Fig. 1B, right).  
165 From this scaffold, we performed a random mutation screening of seven amino acids (AAs)  
166 in close proximity to the cpEGFP moiety; two of these AAs are on the N-terminal side of  
167 cpEGFP, and the remaining five are on the C-terminal side of cpEGFP (Fig. 1C). From  
168 approximately 200 mutant versions of GRAB<sub>NE0.5m</sub>, we found that GRAB<sub>NE1m</sub>—which  
169 contains a glycine-to-threonine mutation at position C1—provided the best performance  
170 with respect to  $\Delta F/F_0$  and brightness (Fig. 1C, middle and right).

171 Next, we expressed GRAB<sub>NE1m</sub> in HEK293T cells and applied NE in a range of  
172 concentrations. NE induced a fluorescence change in GRAB<sub>NE1m</sub>-expressing cells in a  
173 dose-dependent manner, with an EC<sub>50</sub> of 0.93  $\mu$ M and a maximum  $\Delta F/F_0$  of approximately  
174 230% in response to a saturating concentration of NE (100  $\mu$ M) (Fig. 1D, middle and right).  
175 We also introduced mutations in  $\alpha$ 2AR in order to increase its sensitivity at detecting NE.  
176 We found that a single T6.34K point mutation (Ren et al., 1993)—which is close to the  
177 highly conserved E6.30 site—resulted in a 10-fold increase in sensitivity (EC<sub>50</sub> ~83 nM) to  
178 NE compared with GRAB<sub>NE1m</sub>; this sensor, which we call GRAB<sub>NE1h</sub>, has a maximum  $\Delta F/F_0$   
179 of ~130% in response to 100  $\mu$ M NE. As a control, we also generated GRAB<sub>NEmut</sub>, which  
180 has the mutation S5.46A at the putative ligand-binding pocket and therefore is unable to  
181 bind NE (Fig. 1D); this control sensor has similar brightness and membrane trafficking (Fig.  
182 S1 and S2A), but does not respond to NE even at 100  $\mu$ M (Fig. 1D, middle and right).

183 To examine whether our GRAB<sub>NE</sub> sensors can capture the rapid dynamic properties of NE  
184 signaling, including its release, recycling, and degradation, we bathed GRAB<sub>NE1h</sub>-  
185 expressing HEK293T cells in a solution containing NPEC-caged NE; a focused spot of  
186 405-nm light was applied to locally uncage NE by photolysis (Fig. 2A). Transient photolysis  
187 induced a robust increase in fluorescence in GRAB<sub>NE1h</sub>-expressing cells (mean on time  
188 constant 137ms, single exponential fit), which was blocked by application of the  $\alpha$ 2-  
189 adrenergic receptor antagonist yohimbine (Fig. 2B,C). To characterize both the on and off  
190 rates ( $\tau_{on}$  and  $\tau_{off}$ , respectively) of the GRAB<sub>NE</sub> sensors, we locally applied various  
191 compounds to GRAB<sub>NE</sub>-expressing cells using rapid perfusion and measured the  
192 fluorescence response using high-speed line scanning (Fig. 2D,E). The average delay  
193 intrinsic to the perfusion system (measured by fitting the fluorescence increase in the co-  
194 applied red fluorescent dye Alexa 568) was 34 ms (Fig. 2F). Fitting the fluorescence  
195 change in each sensor with a single exponential function yielded an average  $\tau_{on}$  of 72 and  
196 36 ms for GRAB<sub>NE1m</sub> and GRAB<sub>NE1h</sub>, respectively, and an average  $\tau_{off}$  of 680 and 1890 ms  
197 for GRAB<sub>NE1m</sub> and GRAB<sub>NE1h</sub>, respectively (Fig. 2E,F). The faster on-rate and slower off-  
198 rate of GRAB<sub>NE1h</sub> compared to GRAB<sub>NE1m</sub> is consistent with its relatively higher affinity for  
199 NE.

200 High ligand specificity is an essential requirement for tools designed to detect structurally  
201 similar monoamine-based molecules. Importantly, our GRAB<sub>NE</sub> sensors, which are based  
202 on  $\alpha$ 2AR, respond to both NE and Epi, but do not respond to other neurotransmitters (Fig.  
203 2G). The sensors also respond to the  $\alpha$ 2AR agonist brimonidine but not the  $\beta$ 2-adrenergic  
204 receptor agonist isoprenaline, which indicates receptor-subtype specificity. Moreover, the  
205 NE-induced fluorescence increase in GRAB<sub>NE</sub>-expressing cells was blocked by the  $\alpha$ -  
206 adrenergic receptor antagonist yohimbine, but not the  $\beta$ -adrenergic receptor antagonist ICI  
207 118,551. Additionally, because NE and DA are structurally similar yet functionally distinct,  
208 we characterized how our GRAB<sub>NE</sub> sensors respond to various concentrations of DA and  
209 NE. Wild-type  $\alpha$ 2AR has an 85-fold higher affinity for NE versus DA (Fig. 2H, right); in  
210 contrast, GRAB<sub>NE1m</sub> has a 350-fold higher affinity for NE, whereas GRAB<sub>NE1h</sub> was similar  
211 to the wild-type receptor, with a 37-fold higher affinity for NE (Fig. 2H). In contrast, fast-  
212 scan cyclic voltammetry (FSCV) was unable to differentiate between NE and DA,  
213 producing a nearly identical response to similar concentrations of NE and DA (Fig. 2I)  
214 (Robinson et al., 2003). To test the photostability of our NE sensors, we continuously  
215 illuminated GRAB<sub>NE</sub>-expressing HEK293T cells using either 1-photon (confocal) or 2-  
216 photon laser microscopy and found that the GRAB<sub>NE</sub> sensors are more photostable than  
217 EGFP under both conditions (Fig. S2C). Taken together, these data suggest that the  
218 GRAB<sub>NE</sub> sensors can be used to measure the dynamic properties of noradrenergic activity  
219 with high specificity for NE over other neurotransmitters.

220 Next, we examined whether our GRAB<sub>NE</sub> sensors can trigger GPCR-mediated downstream  
221 signaling pathways. First, we bathed GRAB<sub>NE1m</sub>-expressing cells in a saturating  
222 concentration of NE for 2 h, but found no significant internalization of GRAB<sub>NE1m</sub> (Fig. 2J).



223 Similarly, we found that both GRAB<sub>NE1m</sub> and GRAB<sub>NE1h</sub> lack  $\beta$ -arrestin-mediated signaling,  
224 even at the highest concentration of NE tested (Fig. 2K), suggesting that the GRAB<sub>NE</sub>  
225 sensors are not coupled to  $\beta$ -arrestin signaling. In addition, GRAB<sub>NE1m</sub> and GRAB<sub>NE1h</sub> had  
226 drastically reduced downstream Gi coupling compared to wild-type  $\alpha$ 2AR, which was  
227 measured using a Gi-coupling-dependent luciferase complementation assay (Fig. 2L)  
228 (Wan et al., 2018). We also found that G protein activation by GRAB<sub>NE1m</sub> measured using  
229 the highly sensitive TGF $\alpha$  shedding was reduced by about 100-fold compared to the wild-  
230 type receptor (Fig. S2B) (Inoue et al., 2012). Finally, blocking G protein activation by  
231 treating cells with pertussis toxin (Fig. 2M) had no effect on the fluorescence response of  
232 either GRAB<sub>NE1m</sub> or GRAB<sub>NE1h</sub>, indicating that the fluorescence response of GRAB<sub>NE</sub>  
233 sensors does not require G protein coupling (Rasmussen et al., 2011a). Taken together,  
234 these data indicate that GRAB<sub>NE</sub> sensors can be used to report NE concentration without  
235 inadvertently engaging GPCR downstream signaling.

236

### 237 ***Characterization of GRAB<sub>NE</sub> sensors in cultured neurons***

238 The expression, trafficking, and response of proteins can differ considerably between  
239 neurons and cell lines (Marvin et al., 2013; Zou et al., 2014). Therefore, to characterize the  
240 performance of GRAB<sub>NE</sub> sensors in neurons, we co-expressed GRAB<sub>NE</sub> together with  
241 several neuronal markers in cultured cortical neurons. Both GRAB<sub>NE1m</sub> and GRAB<sub>NEmut</sub>  
242 trafficked to the cell membrane and co-localized with the membrane-targeted marker RFP-  
243 CAAX (Fig. 3A,B). Upon bath-application of a saturating concentration of NE, GRAB<sub>NE1m</sub>  
244 and GRAB<sub>NE1h</sub> had a peak  $\Delta F/F_0$  of approximately 230% and 150%, respectively, whereas  
245 GRAB<sub>NEmut</sub> had no response (Fig. 3D,E); these results are similar to our results obtained  
246 with HEK293T cells. Moreover, the NE-induced response in GRAB<sub>NE1m</sub>-expressing cells  
247 was similar among various subcellular compartments identified by co-expressing  
248 GRAB<sub>NE1m</sub> with either the axonal marker synaptophysin (SYP) or the dendritic marker  
249 PSD95 suggesting that GRAB<sub>NE</sub> sensors enable the detection of NE throughout the  
250 neurons (Fig. 3C). Both GRAB<sub>NE1m</sub>- and GRAB<sub>NE1h</sub>-expressing neurons had a dose-  
251 dependent fluorescence increase in response to NE, with mean EC<sub>50</sub> values of 1.9  $\mu$ M and  
252 93 nM, respectively (Fig. 3F). Consistent with high selectivity for NE, GRAB<sub>NE1m</sub> and  
253 GRAB<sub>NE1h</sub> have a 1000-fold and 7-fold higher affinity, respectively, for NE versus DA (Fig.  
254 3F). Moreover, GRAB<sub>NE1m</sub> responded specifically to NE and Epi, but did not respond to  
255 several other neurotransmitters and ligands, including the  $\beta$ 2-adrenergic receptor agonist  
256 isoprenaline, histamine, dopamine, and serotonin (Fig. 3G). Finally, culturing GRAB<sub>NE1m</sub>-  
257 expressing neurons in 100  $\mu$ M NE for one hour did not cause internalization of the sensor,  
258 and the fluorescence increase was both stable for the entire hour and blocked completely  
259 by the  $\alpha$ 2-adrenergic receptor antagonist yohimbine (Fig. 3H,I). Thus, our GRAB<sub>NE</sub> sensors  
260 have the necessary affinity and specificity to faithfully measure noradrenergic signaling in  
261 neurons.

262

263 **Characterization of GRAB<sub>NE</sub> sensors in both cultured and acute brain slices**

264 To further test the GRAB<sub>NE</sub> sensors *in vitro*, we expressed GRAB<sub>NE1m</sub> and GRAB<sub>NE1h</sub> in  
265 cultured hippocampal slices using a Sindbis virus expression system (Fig. S3A). In both  
266 GRAB<sub>NE1m</sub>-expressing CA1 neurons and GRAB<sub>NE1h</sub>-expressing CA1 neurons, exogenous  
267 application of NE in ACSF—but not ACSF alone—evoked a robust increase in fluorescence  
268 (Fig. S3B-D). In contrast, NE had no detectable effect on GRAB<sub>NEmut</sub>-expressing neurons  
269 (Fig. S3C,D). Application of several  $\alpha$ -adrenergic receptor agonists, including epinephrine  
270 and brimonidine, also generated a fluorescence increase in GRAB<sub>NE1m</sub>-expressing  
271 neurons (Fig. S3C,F), consistent with data obtained using cultured cells. The rise and  
272 decay kinetics of the change in fluorescence were second-order, which reflects the  
273 integration of the time required to puff the drugs onto the cells and the sensor's response  
274 kinetics (Fig. S3E,G). We also prepared acute hippocampal slices in which GRAB<sub>NE1h</sub> was  
275 expressed using an adeno-associated virus (AAV); in this acute slice preparation, the  
276 GRAB<sub>NE1h</sub>-expressing hippocampal neurons are innervated by noradrenergic fibers, which  
277 was confirmed by post-hoc staining using an antibody against dopamine beta hydroxylase  
278 (Fig. S3H,I). Application of electrical stimuli at 20 Hz for 1 s elicited a robust increase in  
279 GRAB<sub>NE1h</sub> fluorescence, and this increase was blocked by the application of yohimbine  
280 (Fig. S3J). Consistent with our results obtained using cultured slices, exogenous  
281 application of various  $\alpha$ -adrenergic receptor agonists, including NE, Epi, and brimonidine—  
282 but not the  $\beta$ -adrenergic receptor agonist isoprenaline—evoked a fluorescence increase in  
283 GRAB<sub>NE1h</sub>-expressing neurons, and this response was blocked by yohimbine, but not by  
284 the  $\beta$ -adrenergic receptor antagonist ICI 118,551 (Fig. S3K).

285 Next, we examined whether our GRAB<sub>NE</sub> sensors can be used to monitor the dynamics of  
286 endogenous NE. We expressed GRAB<sub>NE1m</sub> in the locus coeruleus (LC), which contains the  
287 majority of adrenergic neurons within the brain (Fig. 4A). Two weeks after AAV injection,  
288 we prepared acute brain slices and observed GRAB<sub>NE1m</sub> expression in the membrane of  
289 LC neurons using two-photon microscopy (Fig. 4A). We then used electrical stimuli to  
290 evoke the release of endogenous NE in the LC in the acute slices. Applying one or two  
291 stimuli did not produce a detectable fluorescence increase in GRAB<sub>NE1m</sub>-expressing  
292 neurons; in contrast, applying 10 or more stimuli at 20 Hz caused a progressively stronger  
293 response (Fig. 4B). Application of the voltage-activated potassium channel blocker 4-  
294 aminopyridine, which increases Ca<sup>2+</sup> influx during the action potential, significantly  
295 increased the fluorescence response, whereas application of Cd<sup>2+</sup> to block calcium  
296 channels abolished the stimulation-induced fluorescence increase (Fig. 4C), consistent  
297 with presynaptic NE release being mediated by Ca<sup>2+</sup> influx. We also performed line-  
298 scanning experiments in order to track the kinetics of NE release (Fig. 4D, left). A brief  
299 electrical stimulation induced a rapid fluorescence response with a mean  $\tau_{on}$  and  $\tau_{off}$  of 37  
300 ms and 600 ms, respectively (Fig. 4D, middle and right). Taken together, these data  
301 indicate that GRAB<sub>NE1m</sub> can be used to monitor the release of endogenous NE in real time.

302 NE released into the synapse is recycled back into the presynaptic terminal by the  
303 norepinephrine transporter (NET). We therefore tested the sensitivity of GRAB<sub>NE1m</sub> to NET  
304 blockade using desipramine. In the presence of desipramine, electrical stimuli caused a  
305 larger fluorescence response in GRAB<sub>NE1m</sub>-expressing neurons compared to ACSF alone  
306 (Fig. 4E). Moreover, desipramine significantly slowed the  $\tau_{off}$  of the fluorescence signal,  
307 consistent with reduced reuptake of extracellular NE into the presynaptic terminal. To rule  
308 out the possibility that the change in the fluorescence response was caused by a change  
309 in synaptic modulation over time, we applied repetitive electrical stimuli at 5-min intervals  
310 to GRAB<sub>NE1m</sub>-expressing neurons and found that the stimulation-evoked response was  
311 stable for up to 40 min (Fig. 4F). Finally, we examined the specificity of the stimulation-  
312 induced response. Compared with a robust response in control conditions, the  $\alpha$ -  
313 adrenergic antagonist yohimbine blocked the response; moreover, no response was  
314 elicited in LC neurons expressing GRAB<sub>NEmut</sub> or in LC neurons expressing a dopamine  
315 version of the sensor (GRAB<sub>DA1m</sub>) (Fig. 4G). In contrast, cells expressing GRAB<sub>DA1m</sub>  
316 responded robustly to the application of DA, and the GRAB<sub>NE1m</sub> and GRAB<sub>DA1m</sub> responses  
317 were abolished by yohimbine and the dopamine receptor antagonist haloperidol,  
318 respectively (Fig. 4H). Taken together, these data indicate that GRAB<sub>NE1m</sub> is both sensitive  
319 and specific for detecting endogenous noradrenergic activity in LC neurons.

320

### 321 ***GRAB<sub>NE1m</sub> detects both exogenous NE application and endogenous NE release in*** 322 ***awake zebrafish***

323 Zebrafish is both a genetically accessible vertebrate species and an optically transparent  
324 organism, thus serving as a suitable model for *in vivo* imaging. We generated the  
325 transgenic zebrafish line Tg(HuC:NE1m), which pan-neuronally expresses the GRAB<sub>NE1m</sub>  
326 sensor. Pan-neuronal expression was confirmed by GRAB<sub>NE1m</sub> fluorescence on the cell  
327 membrane of neurons throughout the brain (Fig. 5A). Bath application of 50  $\mu$ M NE—but  
328 not DA at the same concentration—elicited a robust increase in fluorescence intensity that  
329 was blocked completely by the subsequent application of 50  $\mu$ M yohimbine (Fig. 5B-D). In  
330 addition, a separate zebrafish line expressing GRAB<sub>NEmut</sub> did not respond to NE (Fig. 5C,D).  
331 Taken together, these data indicate that GRAB<sub>NE1m</sub> can be used to measure NE in an *in*  
332 *vivo* model.

333 Next, we investigated whether GRAB<sub>NE1m</sub> can be used to measure the dynamics of  
334 endogenous noradrenergic activity induced by a visual looming stimulus, which triggers a  
335 robust escape response in zebrafish. We applied repetitive looming stimuli while using  
336 confocal imaging to measure the fluorescence of GRAB<sub>NE1m</sub>-expressing neurites in the  
337 optic tectum (Fig. 5E). Each looming stimulus induced a time-locked increase in GRAB<sub>NE1m</sub>  
338 fluorescence, which was blocked by bath application of yohimbine but was unaffected by  
339 the  $\beta$ -adrenergic receptor antagonist ICI 118,551 (Fig. 5F,G). In contrast, the same looming  
340 stimuli had no effect in animals expressing GRAB<sub>NEmut</sub> (Fig. 5F,G). In addition, adding

341 desipramine to block NE reuptake slowed the decay of the fluorescence signal (Fig. 5H).  
342 By sparse expression of GRAB<sub>NE1m</sub> in individual neurons in zebrafish larvae via transient  
343 transfection, we were also able to record robust signals corresponding to NE release at  
344 single-cell resolution in response to repetitive looming stimuli (Fig. 5I-K), confirming that  
345 our GRAB<sub>NE</sub> sensors can be used to sense NE release at a single-cell level with high  
346 spatiotemporal resolution.

347

### 348 ***GRAB<sub>NE1m</sub> detects optogenetically evoked NE release in freely moving mice***

349 Having demonstrated the proof-of-concept in a relatively simple *in vivo* vertebrate system,  
350 we next examined whether the GRAB<sub>NE</sub> sensors can be used to monitor the noradrenergic  
351 activity in the mammalian brain by virally expressing GRAB<sub>NE1m</sub> (non-Cre dependent)  
352 together with the optogenetic actuator C1V1 (Cre-dependent) in the LC of Th-Cre mice  
353 (Fig. 6A). Optogenetic stimulation of LC NE neurons using 561 nm laser pulses reliably  
354 evoked an increase in GRAB<sub>NE1m</sub> fluorescence in fiber photometry recording of freely  
355 moving mice. Moreover, Intraperitoneal (i.p.) injection of desipramine produced a slow  
356 progressive increase in basal GRAB<sub>NE1m</sub> fluorescence (consistent with an increase in  
357 extracellular NE levels) and caused an increase in the magnitude and decay time of the  
358 light-activated responses. I.p. injection of yohimbine abolished both the increase in basal  
359 GRAB<sub>NE1m</sub> fluorescence and the light-evoked responses (Fig. 6B-D). In contrast, treating  
360 mice with either GBR 12909 (a selective blocker of dopamine transporters) or eticlopride  
361 (a specific D2R antagonist) had no effect on the light-evoked responses in GRAB<sub>NE1m</sub>  
362 fluorescence (Fig. 6C-E). To further test the selectivity of GRAB<sub>NE1m</sub> between NE and  
363 dopamine, we co-expressed GRAB<sub>NE1m</sub> and DIO-C1V1 both in the LC and in the substantia  
364 nigra pars compacta (SNc) of Th-Cre mice (Fig. 6F). In these mice, optogenetic stimulation  
365 of dopamine neurons in the SNc did not cause any changes in the GRAB<sub>NE1m</sub> fluorescence  
366 in the SNc. In contrast, stimulating NE neurons in the LC produced a clear increase in  
367 GRAB<sub>NE1m</sub> fluorescence (Fig. 6F, G). These results confirm that the increase of GRAB<sub>NE1m</sub>  
368 fluorescence reflects the release of endogenous NE from noradrenergic neurons in the LC.

369

### 370 ***Using GRAB<sub>NE1m</sub> to track endogenous NE dynamics in the mouse hypothalamus*** 371 ***during freely moving behaviors***

372 In the brain, the hypothalamus mediates a variety of innate behaviors essential for survival,  
373 including feeding, aggression, mating, parenting, and defense (Hashikawa et al., 2016;  
374 Sokolowski and Corbin, 2012; Yang and Shah, 2016). The hypothalamus receives  
375 extensive noradrenergic projections (Moore and Bloom, 1979; Schwarz and Luo, 2015;  
376 Schwarz et al., 2015) and expresses an abundance of  $\alpha$ 2-adrenergic receptors (Leibowitz,  
377 1970; Leibowitz et al., 1982). Microdialysis studies found that the hypothalamus is among  
378 the brain regions that contains high level of NE during stress (McQuade and Stanford,

379 2000; Pacak et al., 1995; Shekhar et al., 2002; Tanaka, 1999). To better understand the  
380 dynamics of NE signaling in the hypothalamus under stress, we virally expressed hSyn-  
381 GRAB<sub>NE1m</sub> in the lateral hypothalamus of C57BL/6 mice. Three weeks after virus injection,  
382 we performed fiber photometry recordings of GRAB<sub>NE1m</sub> fluorescence during a variety of  
383 stressful and non-stressful behaviors in freely moving mice (Fig. 7).

384 During forced swim test and tail suspension test (both of which were stressful), we  
385 observed a significant increase in GRAB<sub>NE1m</sub> fluorescence. During forced swim test, the  
386 fluorescence signal increased continuously regardless of the animal's movements and  
387 started to decrease only after the animal was removed from the water (Fig. 7C1-E1). During  
388 the 60-s tail suspension test, the signal began to rise when the animal was first pursued  
389 by the experimenter's hand, increased continuously while the animal was suspended by  
390 the tail, and decreased rapidly back to baseline levels when the animal was returned to its  
391 home cage (Fig. 7C2-E2). Additionally, when a human hand was placed in front of the  
392 animal, we observed a small and transient increase in GRAB<sub>NE1m</sub> fluorescence (Fig. 7C3-  
393 E3). In contrast, the presence of a non-aggressive mouse of either the same or the  
394 opposite sex or close social interaction with the conspecific (7C4-E4, C5-E5) caused no  
395 significant change in GRAB<sub>NE1m</sub> fluorescence. Lastly, neither sniffing nor eating a food  
396 attractant—in this case, peanut butter—had an effect on GRAB<sub>NE1m</sub> fluorescence (Fig.  
397 7C6-E6). These data provide evidence that noradrenergic activity in the lateral  
398 hypothalamus occurs primarily under stressful conditions.

399 Finally, to confirm that the GRAB<sub>NE1m</sub> sensor indeed detects changes in NE concentration  
400 instead of other monoamine neurotransmitters, such as dopamine, we injected mice with  
401 a specific NET inhibitor atomoxetine (3 mg/kg i.p.) to inhibit the reuptake of NE. Although  
402 atomoxetine had no effect on the peak change in GRAB<sub>NE1m</sub> fluorescence during the tail  
403 suspension test, it significantly slowed the return to baseline levels after each tail  
404 suspension (Fig. 7F1-I1); in contrast, treating mice with the  $\alpha$ -adrenergic receptor  
405 antagonist yohimbine (2 mg/kg) both decreased the peak change in GRAB<sub>NE1m</sub>  
406 fluorescence and significantly accelerated the return to baseline (Fig. 7F1-I1). Treating  
407 mice with either the selective DAT inhibitor GBR 12909 (10 mg/kg, i.p.) or the D2 receptor  
408 antagonist sulpiride (50 mg/kg, i.p.) had no effect on the peak change in GRAB<sub>NE1m</sub>  
409 fluorescence or the time to return to baseline (Fig. 7F2-I2). In summary, these data  
410 demonstrate that our GRAB<sub>NE</sub> sensors are suitable for monitoring endogenous  
411 noradrenergic activity in real time, with high spatiotemporal precision, during freely  
412 moving behavior in mammals.

## 413 Discussion

414 Here, we report the development and validation of GRAB<sub>NE1m</sub> and GRAB<sub>NE1h</sub>, two  
415 genetically encoded norepinephrine/epinephrine sensors that can be used both *in vitro* and  
416 *in vivo* to monitor noradrenergic activity with high temporal and spatial resolution, high  
417 ligand specificity, and cell type specificity. In mouse acute brain slices, our GRAB<sub>NE</sub> sensors  
418 detected NE release from the LC in response to electrical stimulation. In zebrafish, the  
419 GRAB<sub>NE</sub> sensors reported looming-induced NE release with single-cell resolution. In mice,  
420 the GRAB<sub>NE</sub> sensors reported the time-locked release of NE in the LC triggered by  
421 optogenetic stimulation, as well as changes in hypothalamic NE levels during a variety of  
422 stress-related behaviors.

423 Compared to existing methods for detecting NE, our GRAB<sub>NE</sub> sensors have several distinct  
424 advantages. First, NE has been difficult to distinguish from DA *in vivo* (e.g. by fast-scan  
425 cyclic voltammetry) (Park et al., 2009; Robinson et al., 2003), largely because of their  
426 structural similarities with only one hydroxyl group difference. Our GRAB<sub>NE</sub> sensors have  
427 extremely high *specificity* for NE over other neurotransmitters and chemical modulators,  
428 including DA (Figs. 2H, 3F). GRAB<sub>NE1m</sub> has a roughly 1000-fold higher affinity for NE over  
429 DA when expressed in neurons, even better than the 85-fold difference of the wild-type  $\alpha$ 2-  
430 adrenergic receptor. Thus, our GRAB<sub>NE</sub> sensors provide new opportunities to probe the  
431 dynamics of noradrenergic activity with high specificity, which is particularly valuable when  
432 studying the many brain regions that receive overlapping dopaminergic and noradrenergic  
433 inputs. One thing to note is that GRAB<sub>NE</sub> sensors are engineered from the  $\alpha$ 2a receptor,  
434 which may not be suitable for pharmacological investigation of  $\alpha$ 2a receptor related  
435 regulations.

436 Second, our GRAB<sub>NE</sub> sensors have extremely high *sensitivity* for NE. Specifically, the EC<sub>50</sub>  
437 for NE approaches sub-micromolar levels, with a 200%—or higher—increase in  
438 fluorescence intensity upon binding NE. By comparison, recently published FRET-based  
439 NE indicators produce a signal change of  $\leq 10\%$  under optimal conditions (Wang et al.,  
440 2018a; Wang et al., 2018b). Thus, GRAB<sub>NE</sub> sensors have much improved characteristics  
441 to monitor endogenous *in vivo* NE dynamics. Third, GRAB<sub>NE</sub> sensors have brightness and  
442 photostability properties that rival EGFP, which permits stable recordings across extended  
443 experimental sessions. Fourth, because they provide sub-second response kinetics and  
444 are genetically encoded, our GRAB<sub>NE</sub> sensors can non-invasively report noradrenergic  
445 activity *in vivo* with single-cell resolution and a high recording rate (~30 Hz). Finally,  
446 because the GRAB<sub>NE</sub> sensors can traffic to various surface membranes, including the cell  
447 body, dendrites, and axons, and because they perform equally well in these membrane  
448 compartments, they can provide subcellular spatial resolution, which is essential for  
449 understanding compartmental NE signaling *in vivo*.

450 Ligand binding to endogenous GPCRs drives G-protein activation and receptor  
451 internalization. If present in GRAB<sub>NE</sub> sensors, these responses could interfere with

452 endogenous signaling fidelity and disrupt normal neuronal activity. To assess this risk, we  
453 characterized the downstream coupling of our GRAB<sub>NE</sub> sensors with both G protein–  
454 independent and G protein–dependent pathways. Importantly, the introduction of the  
455 cpEGFP moiety in the GRAB<sub>NE</sub> sensors resulted in non-detectable engagement of  
456 arrestin-mediated desensitization/internalization, which ensures more consistent surface  
457 expression of the sensor and that the GRAB<sub>NE</sub> sensors do not inadvertently activate  
458 arrestin-dependent signaling. With respect to G protein–dependent signaling, we found  
459 that although physiological levels of NE robustly induce a change in GRAB<sub>NE1m</sub>  
460 fluorescence, they do not engage downstream G protein signaling (Fig. 2J-M).

461 Noradrenergic projections throughout the brain originate almost exclusively from the LC,  
462 and NE release plays a role in a wide range of behaviors, including cognition and the  
463 regulation of arousal, attention, and alertness (Berridge and Waterhouse, 2003; Li et al.,  
464 2018; Schwarz et al., 2015). In this respect, it is interesting to note that our *in vivo*  
465 experiments revealed that GRAB<sub>NE</sub> sensors can reliably report looming-evoked NE release  
466 in the optic tectum of live zebrafish. Moreover, our fiber photometry recordings of GRAB<sub>NE</sub>  
467 sensors in the hypothalamus of freely behaving mice revealed specific changes in  
468 noradrenergic activity under stressful conditions (e.g., a tail lift or forced swimming),  
469 whereas non-stressful conditions such as feeding and social interaction did not appear to  
470 alter noradrenergic activity. These data are generally consistent with previous data  
471 obtained using microdialysis to measure NE (McQuade and Stanford, 2000; Pacak et al.,  
472 1995; Shekhar et al., 2002; Tanaka, 1999). Importantly, however, our approach yielded a  
473 more temporally precise measurement of noradrenergic activity with the promise of higher  
474 spatial and cell-type specificity.

475 NE circuits of the LC receive heterogeneous inputs from a broad range of brain regions  
476 and send heterogeneous outputs to many brain regions (Schwarz et al., 2015).  
477 Congruously, altered noradrenergic activity has been associated with a broad range of  
478 brain disorders and conditions, including ADHD, PD, depression, and anxiety (Marien et  
479 al., 2004). The complexity of these disorders may, in part, reflect the complexities of  
480 noradrenergic circuits and signals, which previous tools have been unable to fully dissect.  
481 Thus, understanding the regulation and impact of noradrenergic activity during complex  
482 behavior demands technological advances, such as the GRAB<sub>NE</sub> sensors we present here.  
483 Deploying these in concert with other cell-specific tools for reporting (Jing et al., 2018;  
484 Patriarchi et al., 2018; Sun et al., 2018) and manipulating neurotransmitter levels (Fenno  
485 et al., 2011; Urban and Roth, 2015) should increase our understanding of the circuits and  
486 mechanisms that underlie brain functions in both health and diseases.

## 487 **Experimental model and subject details**

### 488 ***Primary cultures***

489 Rat cortical neurons were prepared from postnatal day 0 (P0) Sprague-Dawley rat pups  
490 (both male and female, randomly selected; Beijing Vital River). In brief, cortical neurons  
491 were dissociated from dissected P0 rat brains in 0.25% Trypsin-EDTA (Gibco), plated on  
492 12-mm glass coverslips coated with poly-D-lysine (Sigma-Aldrich), and cultured at 37°C in  
493 5% CO<sub>2</sub> in neurobasal medium (Gibco) containing 2% B-27 supplement, 1% GlutaMax,  
494 and 1% penicillin-streptomycin (Gibco).

### 495 ***Cell lines***

496 HEK293T cells were obtained from ATCC (CRL-3216) and verified based on their  
497 morphology under the microscope and by their growth curve. Stable cell lines expressing  
498 the wild-type  $\alpha 2$ -adrenergic receptor or various GRAB<sub>NE</sub> sensors were constructed by co-  
499 transfecting cells with the pPiggyBac plasmid carrying target genes with Tn5 transposase  
500 into a stable HEK293T-based cell line expressing chimeric Gαq/i and AP-TGFα (Inoue et  
501 al., 2012). Cells that stably expressed the target genes were selected by treating with 2  
502 mg/ml Puromycin (Sigma) after reaching 100% confluence. The HTLA cells used for the  
503 TANGO Assay stably express a tTA-dependent luciferase reporter and a  $\beta$ -arrestin2-TEV  
504 fusion gene and were a gift from Bryan L. Roth (Kroeze et al., 2015). All cell lines were  
505 cultured at 37°C in 5% CO<sub>2</sub> in DMEM (Gibco) supplemented with 10% (v/v) fetal bovine  
506 serum (Gibco) and 1% penicillin-streptomycin (Gibco).

### 507 ***Mice***

508 All procedures regarding animals were approved by the respective Animal Care and Use  
509 Committees at Peking University, New York University, University of Southern California  
510 and the US National Institutes of Health, and were performed in compliance with the US  
511 National Institutes of Health guidelines for the care and use of laboratory animals. Wild-  
512 type Sprague-Dawley rat pups (P0) were used to prepare cultured cortical neurons. Wild-  
513 type C57BL/6 and Th-Cre mice (MMRRC\_031029-UCD, obtained from MMRRC) were  
514 used to prepare the acute brain slices and for the *in vivo* mouse experiments. Experimental  
515 Th-Cre mice were produced by breeding Th-Cre hemizygous BAC transgenic mice with  
516 C57BL/6J mice. All animals were housed in the animal facility and were family-housed or  
517 pair-housed in a temperature-controlled room with a 12hr-12h light-dark cycle (10 pm to  
518 10 am light) with food and water provided *ad libidum*. All *in vivo* mouse experiments were  
519 performed using 2-12-month-old mice of both sexes.

### 520 ***Zebrafish***

521 The background strain for these experiments is the albino strain slc45a2b4. To generate  
522 transgenic zebrafish, Both the pTol2-HuC:GRAB<sub>NE1m</sub> plasmid and Tol2 mRNA were co-  
523 injected into single-cell stage zebrafish eggs, and the founders of HuC:NE1m were



524 screened. HuC:NEmut transgenic fish were generated as described above using the  
525 pTol2-HuC:GRAB<sub>NEmut</sub> plasmid. Adult fish and larvae were maintained on a 14h-10h  
526 light-dark cycle at 28°C. All experimental larvae were raised to 6-8 days post-fertilization  
527 (dpf) in 10% Hank's solution, which consisted of (in mM): 140 NaCl, 5.4 KCl, 0.25  
528 Na<sub>2</sub>HPO<sub>4</sub>, 0.44 KH<sub>2</sub>PO<sub>4</sub>, 1.3 CaCl<sub>2</sub>, 1.0 MgSO<sub>4</sub>, and 4.2 NaHCO<sub>3</sub> (pH 7.2). Larval  
529 zebrafish do not undergo sex differentiation prior to 1 month post-fertilization (Singleman  
530 and Holtzman, 2014).

531

## 532 **Method details**

### 533 ***Molecular cloning***

534 The molecular clones used in this study were generated by Gibson Assembly using DNA  
535 fragments amplified using primers (Thermo Fisher Scientific) with 25-bp overlap. The  
536 Gibson Assembly cloning enzymes consisted of T5-exonuclease (New England Biolabs),  
537 Phusion DNA polymerase (Thermo Fisher Scientific), and Taq ligase (iCloning). Sanger  
538 sequencing was performed using the sequencing platform at the School of Life Sciences  
539 of Peking University in order to verify the sequence of all clones. All cDNAs encoding the  
540 candidate GRAB<sub>NE</sub> sensors were cloned into the pDisplay vector (Invitrogen) with an  
541 upstream IgK leader sequence and a downstream IRES-mCherry-CAAX cassette to label  
542 the cell membrane. The cDNAs of select adrenergic receptor candidates were amplified  
543 from the human GPCR cDNA library (hORFeome database 8.1), and cpEGFP from  
544 GCaMP6s was inserted into the third intracellular loop (ICL3). The insertion sites for the  
545 GRAB<sub>NE</sub> sensors were screened by truncating the ICL3 of the  $\alpha$ 2-adrenergic receptor at  
546 the 10-amino acid (AA) level, followed by fine-tuning at the 1-AA level. Coupling linkers  
547 were randomized by PCR amplification using randomized NNB codons in target sites.  
548 Other cDNAs used to express the GRAB<sub>NE</sub> sensors in neurons were cloned into the pAAV  
549 vector using the human synapsin promoter (hSyn) or TRE promoter. pAAV-CAG-tTA was  
550 used to drive expression of the TRE promoter. The plasmids carrying compartmental  
551 markers were cloned by fusing EGFP-CAAX, RFP-CAAX (mScarlet), KDELR-EGFP,  
552 PSD95-RFP, and synaptophysin-RFP into the pDest vector. To characterize signaling  
553 downstream of the GRAB<sub>NE</sub> sensors, we cloned the sensors and the wild-type  $\alpha$ 2-  
554 adrenergic receptor into the pTango and pPiggyBac vector, respectively. GRAB<sub>NE1m</sub>-SmBit  
555 and  $\alpha$ 2AR-SmBit constructs were derived from  $\beta$ 2AR-SmBit (Wan et al., 2018) using a  
556 BamHI site incorporated upstream of the GGSG linker. LgBit-mGsi was a gift from Nevin  
557 A. Lambert.

### 558 ***Expression of GRAB<sub>NE</sub> sensors in cultured cells and in vivo***

559 The GRAB<sub>NE</sub> sensors were characterized in HEK293T cells and cultured rat cortical  
560 neurons, with the exception of the TANGO assay and TGF $\alpha$  shedding assay. HEK293T  
561 cells were passaged with Trypsin-EDTA (0.25%, phenol red; Gibco) and plated on 12-mm

562 size 0 glass coverslips in 24-well plates and grown to ~70% confluence for transfection.  
563 HEK293T cells were transfected by incubating cells with a mixture containing 1  $\mu$ g of DNA  
564 and 3  $\mu$ g of PEI for 6 h. Imaging was performed 24–48 h after transfection. Cells expressing  
565 GRAB<sub>NE</sub> sensors for screening were plated on 96-well plates (PerkinElmer).

566 Cultured neurons were transfected using the calcium phosphate method at 7–9 DIV. In brief,  
567 the neurons were incubated for 2 h in a mixture containing 125 mM CaCl<sub>2</sub>, HBS (pH 7.04),  
568 and 1.5  $\mu$ g DNAh. The DNA-Ca<sub>3</sub>(PO<sub>4</sub>)<sub>2</sub> precipitate was then removed from the cells by  
569 washing twice with warm HBS (pH 6.80). Cells were imaged 48 h after transfection.

570 For *in vivo* expression, the mice were anesthetized by an i.p. injection of 2,2,2-  
571 tribromoethanol (Avetin, 500 mg/kg body weight, Sigma-Aldrich), and then placed in a  
572 stereotaxic frame for injection of AAVs using a Nanoliter 2000 Injector (WPI) or Nanoject II  
573 (Drummond Scientific) microsyringe pump. For the experiments shown in Figures 4 and 6,  
574 the AAVs containing hSyn-GRAB<sub>NE1m/NE1mut/DA1m</sub> and Ef1a-DIO-C1V1-YFP were injected  
575 into the LC (AP: -5.45 mm relative to Bregma; ML:  $\pm$ 1.25 mm relative to Bregma; and DV:  
576 -2.25 mm from the brain surface) or SNc (AP: -3.1 mm relative to Bregma; ML:  $\pm$ 1.5 mm  
577 relative to Bregma; and DV: -3.8 mm from the brain surface) of wild-type or Th-Cre mice.  
578 For the experiments shown in Figure 7, 100 nl of AAV9-hSyn-GRAB<sub>NE1m</sub> (Vigene,  $1 \times 10^{13}$   
579 titer genomic copies per ml) were unilaterally into the hypothalamus (AP: -1.7 mm relative  
580 to Bregma; ML: 0.90 mm relative to Bregma; and DV: -6.05 mm from the brain surface) of  
581 wild-type (C57BL/6) mice at a rate of 10 nl/min.

## 582 **Fluorescence imaging of HEK293T cells and cultured neurons**

583 HEK293T cells and cultured neurons expressing GRAB<sub>NE</sub> sensors were screened using  
584 an Opera Phenix high-content imaging system (PerkinElmer) and imaged using an inverted  
585 Ti-E A1 confocal microscope (Nikon). A 60x/1.15 NA water-immersion objective was  
586 mounted on the Opera Phenix and used to screen GRAB<sub>NE</sub> sensors with a 488-nm laser  
587 and a 561-nm laser. A 525/50 nm and a 600/30 nm emission filter were used to collect the  
588 GFP and RFP signals, respectively. HEK293T cells expressing GRAB<sub>NE</sub> sensors were first  
589 bathed in Tyrode's solution and imaged before and after addition of the indicated drugs at  
590 the indicated concentrations. The change in fluorescence intensity of the GRAB<sub>NE</sub> sensors  
591 was calculated using the change in the GFP/RFP ratio. For confocal microscopy, the  
592 microscope was equipped with a 40x/1.35 NA oil-immersion objective, a 488-nm laser, and  
593 a 561-nm laser. A 525/50 nm and a 595/50 nm emission filter were used to collect the GFP  
594 and RFP signals, respectively. GRAB<sub>NE</sub>-expressing HEK293T cells and neurons were  
595 perfused with Tyrode's solutions containing the drug of interest in the imaging chamber.  
596 The photostability of GRAB<sub>NE</sub> sensors and EGFP was measured using a confocal  
597 microscope (for 1-photon illumination) equipped with a 488-nm laser at a power setting of  
598 ~350  $\mu$ W, and using a FV1000MPE 2-photon microscope (Olympus, 2-photon illumination)  
599 equipped with a 920-nm laser at a power setting of ~27.5 mW. The illuminated region was  
600 the entire HEK293T cell expressing the target protein, with an area of ~200  $\mu$ m<sup>2</sup>. Photolysis

601 of NPEC-caged-NE (Tocris) was performed by combining fast scanning with a 76-ms pulse  
602 of 405-nm laser illumination by a confocal microscope.

### 603 **TANGO assay**

604 NE at various concentrations (ranging from 0.1 nM to 100  $\mu$ M) was applied to  $\alpha$ 2AR-  
605 expressing or NE1m-/NE1h-expressing HTLA cells (Kroeze et al., 2015). The cells were  
606 then cultured for 12 hours to allow expression of the luciferase gene. Furimazine (NanoLuc  
607 Luciferase Assay, Promega) was then applied to a final concentration of 5  $\mu$ M, and  
608 luminescence was measured using a VICTOR X5 multilabel plate reader (PerkinElmer).

### 609 **TGF $\alpha$ shedding assay**

610 Stable cell lines expressing Gai-AP-TGF $\alpha$  together with the wild-type  $\alpha$ 2AR or GRAB<sub>NE</sub>  
611 sensors were plated in a 96-well plate and treated by the addition of 10  $\mu$ l of a 10x solution  
612 of NE in each well, yielding a final NE concentration ranging from 0.1 nM to 100  $\mu$ M.  
613 Absorbance at 405 nm was read using a VICTOR X5 multilabel plate reader (PerkinElmer).  
614 TGF $\alpha$  release was calculated as described previously (Inoue et al., 2012). Relative levels  
615 of G protein activation were calculated as the TGF $\alpha$  release of GRAB<sub>NE</sub> sensors normalized  
616 to the release mediated by wild-type  $\alpha$ 2AR.

### 617 **FSCV**

618 Fast-scan cyclic voltammetry was performed using 7- $\mu$ m carbon fiber microelectrodes.  
619 Voltammograms were measured with a triangular potential waveform from -0.4 V to +1.1  
620 V at a scan rate of 400 V/s and a 100-ms interval. The carbon fiber microelectrode was  
621 held at -0.4 V between scans. Voltammograms measured in the presence of various  
622 different drugs in Tyrode's solution were generated using the average of 200 scans  
623 followed by the subtraction of the average of 200 background scans. Currents were  
624 recorded using the Pinnacle tethered FSCV system (Pinnacle Technology). Pseudocolor  
625 plots were generated using Pinnacle FSCV software. The data were processed using Excel  
626 (Microsoft) and plotted using Origin Pro (OriginLab).

### 627 **Luciferase complementation assay**

628 The luciferase complementation assay was performed as previously described (Wan et al.,  
629 2018). In brief, ~48h after transfection the cells were washed with PBS, harvested by  
630 trituration, and transferred to opaque 96-well plates containing diluted NE solutions.  
631 Furimazine (Nano-Glo; 1:1000; Promega) was added to each well immediately prior to  
632 performing the measurements with Nluc.

### 633 **Fluorescence imaging of GRAB<sub>NE</sub> in brain slices**

634 Fluorescence imaging of acute brain slices was performed as previously described (Sun  
635 et al., 2018). In brief, the animals were anesthetized with Avertin, and acute brain slices  
636 containing the LC region or the hippocampus region were prepared in cold slicing buffer

637 containing (in mM): 110 choline-Cl, 2.5 KCl, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 25 NaHCO<sub>3</sub>, 7 MgCl<sub>2</sub>, 25  
638 glucose, and 2 CaCl<sub>2</sub>. Slices were allowed to recover at 35°C in oxygenated Ringers  
639 solution containing (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH<sub>2</sub>PO<sub>4</sub>, 25 NaHCO<sub>3</sub>, 1.3 MgCl<sub>2</sub>,  
640 25 glucose, and 2 CaCl<sub>2</sub> for at least 40 minutes before experiments. An Olympus  
641 FV1000MPE two-photon microscope equipped with a 40x/0.80 NA water-immersion  
642 objective and a mode-locked Mai Tai Ti:Sapphire laser (Spectra-Physics) tuned to 920  
643 nm were used for imaging the slices. For electrical stimulation, a concentric electrode  
644 (model #CBAEC75, FHC) was positioned near the LC region, and the imaging and  
645 stimuli were synchronized using an Arduino board controlled using a custom-written  
646 program. The imaging speed was set at 0.148 s/frame with 128 x 96 pixels in each frame.  
647 The stimulation voltage was set at ~6 V, and the duration of each stimulation was  
648 typically 1 ms. Drugs were either delivered via the perfusion system or directly bath-  
649 applied in the imaging chamber.

650 For immunostaining of brain sections, GRAB<sub>NE</sub>-expressing mice were anesthetized with  
651 Avetin, and the heart was perfused with 0.9% NaCl followed by 4% paraformaldehyde  
652 (PFA). The brain was then removed, placed in 4% PFA for 4 h, and then cryoprotected  
653 in 30% (w/v) sucrose for 24 h. The brain was embedded in tissue-freezing medium, and  
654 50- $\mu$ m thick coronal sections were cut using a Leica CM1900 cryostat (Leica, Germany).  
655 A chicken anti-GFP antibody (1:500, Abcam, #ab13970) was used to label GRAB<sub>NE</sub>, and  
656 a rabbit anti-DBH antibody (1:50, Abcam, #ab209487) was used to label adrenergic  
657 terminals in the hippocampus. Alexa-488-conjugated goat-anti-chicken and Alexa-555-  
658 conjugated goat-anti-rabbit secondary antibodies were used as the secondary antibody,  
659 and the nuclei were counterstained with DAPI. The sections were imaged using a  
660 confocal microscope (Nikon).

### 661 ***Fluorescence imaging of zebrafish***

662 Tg(HuC:GRAB-NE<sub>1m</sub>) zebrafish larvae were imaged by using an upright confocal  
663 microscope (Olympus FV1000, Japan) equipped with a 20x water-dipping objective  
664 (0.95 NA). The larvae were first paralyzed with  $\alpha$ -bungarotoxin (100  $\mu$ g/ml, Sigma),  
665 mounted dorsal side up in 1.5% low melting-point agarose (Sigma), and then perfused  
666 with an extracellular solution consisting of (in mM) 134 NaCl, 2.9 KCl, 4 CaCl<sub>2</sub>, 10  
667 HEPES, and 10 glucose (290 mOsmol/L, pH 7.8). Images were acquired at 1-2 Hz with  
668 a view field of 800  $\times$  800 pixels and a voxel size was 0.62  $\times$  0.62  $\times$  2.0  $\mu$ m<sup>3</sup> (x  $\times$  y  $\times$  z).  
669 To detect the sensor's response to exogenous NE, 50  $\mu$ M L-(-)-norepinephrine (+)-  
670 bitartrate salt monohydrate (Sigma) in 5  $\mu$ M L-ascorbic acid and 50  $\mu$ M yohimbine  
671 hydrochloride (TOCRIS) were sequentially applied to the bath. To detect endogenous NE  
672 release, visual looming stimuli, which mimic approaching objects or predators (Yao et al.,  
673 2016) were projected to the larvae under a red background. Each trial lasted 5 s, and 5  
674 trials were performed in a block, with a 90-s interval between trials. To examine the  
675 specificity of responses, ICI 118,551 hydrochloride (50  $\mu$ M, Sigma) and desipramine  
676 hydrochloride (50  $\mu$ M, Sigma) were applied. Looming stimuli in transiently transfected

677 HuC:GRAB<sub>NE1m</sub> zebrafish were measured at single-cell resolution by using the same  
678 conditions described above.

### 679 ***Fiber photometry recording in freely moving mice during optical stimulation***

680 In the all-optic experiments shown in Figure 6, multimode optical fiber probes (105/125  $\mu\text{m}$   
681 core/cladding) were implanted into the LC (AP: -5.45 mm relative to Bregma; ML:  $\pm 0.85$   
682 mm relative to Bregma; and DV: -3.5 mm from the brain surface) and the SNc (AP: -3.1  
683 mm relative to Bregma; ML:  $\pm 1.5$  mm relative to Bregma; and DV: -3.85 mm from the brain  
684 surface) in mice four weeks after viral injection. Fiber photometry recording in the LC and/or  
685 SNc was performed using a 473-nm laser with an output power of 25  $\mu\text{W}$  measured at the  
686 end of the fiber. The measured emission spectra were fitted using a linear unmixing  
687 algorithm (<https://www.niehs.nih.gov/research/atniehs/labs/In/pi/iv/tools/index.cfm>). The  
688 coefficients generated by the unmixing algorithm were used to represent the fluorescence  
689 intensities of various fluorophores (Meng et al., 2018). To evoke C1V1-mediated NE/DA  
690 release, pulse trains (10-ms pulses at 20 Hz for 1 s) were delivered to the LC/SNc using a  
691 561-nm laser with an output power of 9.9 mW measured at the end of the fiber.

### 692 ***Fiber photometry recording in mice during behavioral testing***

693 For the experiments in Figure 7, a fiber photometry recording set-up was generated and  
694 used as previously described (Falkner et al., 2016). GRAB<sub>NE1m</sub> was injected into the lateral  
695 hypothalamus (Bregma AP: -1.7mm; ML: 0.90 mm DV: -4.80 mm) of C57BL/6 mice in a  
696 volume of 100 nl containing AAV9-hSyn-GRAB<sub>NE1m</sub> (Vigene,  $1 \times 10^{13}$  titer genomic copies  
697 per ml) at 10 nl/min. A 400- $\mu\text{m}$  optic fiber (Thorlabs, BFH48-400) housed in a ceramic  
698 ferrule (Thorlabs, SFLC440-10) was implanted 0.2 mm above the injection site. The virus  
699 was left to incubate for three weeks. Prior to fiber photometry recording, a ferrule sleeve  
700 was used to connect a matching optic fiber to the implanted fiber. For recordings, a 400-  
701 Hz sinusoidal blue LED light (30  $\mu\text{W}$ ; M470F1 driven by an LEDD1B driver; both from  
702 Thorlabs) was bandpass-filtered (passing band:  $472 \pm 15$  nm, Semrock, FF02-472/30-25)  
703 and delivered to the brain in order to excite GRAB<sub>NE1m</sub>. The emission light passed through  
704 the same optic fiber, through a bandpass filter (passing band:  $534 \pm 25$  nm, Semrock,  
705 FF01-535/50), and into a Femtowatt Silicon Photoreceiver, which recorded the GRAB<sub>NE1m</sub>  
706 emission using an RZ5 real-time processor (Tucker-Davis Technologies). The 400-Hz  
707 signals from the photoreceiver were extracted in real time using a custom program (Tucker-  
708 Davis Technologies) and used to reflect the intensity of the GRAB<sub>NE1m</sub> fluorescence signal.

### 709 ***Behavioral assays***

710 All behavioral tests were performed at least one hour after the onset of the dark cycle. For  
711 the tail suspension test, each mouse was gripped by the tail and lifted off the bottom of its  
712 cage six times for 60 s each, with at least one minute between each lift. For the forced  
713 swim test, the mouse was gently placed in a 1000-ml conical flask containing lukewarm  
714 water and removed after 4-6 minutes. After removal from the water, the mouse was gently

715 dried with paper towels and placed in the home cage on a heating pad. For conspecific  
716 assays, an adult C57BL/6 group-housed mouse of either sex was placed inside the test  
717 mouse's cage for 10 minutes. No sexual behavior or aggressive behavior was observed  
718 during the interaction. For the food assay, ~4g of peanut butter was placed in the cap of a  
719 15-ml plastic tube and placed inside of the test mouse's cage for 10 minutes. During that  
720 period, the test mouse was free to explore, sniff, and eat the peanut butter. All videos were  
721 acquired at 25 frames per second and manually annotated frame-by-frame using a custom  
722 MATLAB program (Lin et al., 2011). "Contact" with the social stimulus refers to the period  
723 in which the test mouse sniffed or was sniffed by the intruder. "Contact" with the peanut  
724 butter refers to the period in which the test mouse sniffed or ate the peanut butter. "Lift"  
725 refers to the period in which the experimenter gripped the mouse's tail and lifted the mouse  
726 into the air.

727

## 728 **Quantification and statistical analysis**

729 For the imaging experiments using cultured HEK293T cells, primary neurons, and brain  
730 slices, images were first imported to ImageJ software (National Institutes of Health) for  
731 fluorescence intensity readouts, and then analyzed using MATLAB (MathWorks) with a  
732 custom-written script or Origin Pro (OriginLab). The fluorescence response traces in the  
733 brain slices shown in Figure 4 were processed with 3x binning and then plotted.

734 Time-lapse images of the zebrafish were analyzed using Fiji to acquire the  
735 fluorescence intensity in the region of interest (ROI) in each frame. A custom-  
736 written MATLAB program was then used to calculate the change in fluorescence  
737 intensity ( $\Delta F/F_0$ ) as follows:  $\Delta F/F_0 = (F_t - F_0)/F_0$ , where  $F_t$  was the fluorescence intensity  
738 at time  $t$  and  $F_0$  was the average fluorescence intensity during the entire time window.  
739 Statistical analyses were performed using GraphPad Prism 6 and Origin Pro (OriginLab).

740 For the fiber photometry data shown in Figure 7, the MATLAB function "msbackadj" with a  
741 moving window of 25% of the total recording duration was first applied to obtain the  
742 instantaneous baseline signal ( $F_{\text{baseline}}$ ). The instantaneous  $\Delta F/F$  was calculated as  $(F_{\text{raw}} -$   
743  $F_{\text{baseline}})/F_{\text{baseline}}$ , and a peri-stimulus histogram (PSTH) was calculated by aligning the  $\Delta F/F$   
744 signal of each trial to the onset of the behavior of interest. The response elicited during a  
745 behavior was calculated as the average  $\Delta F/F$  during all trials of a given behavior. The  
746 response between behavioral periods was calculated as the average  $\Delta F/F$  between two  
747 behavioral episodes excluding 4 s immediately before the behavior's onset, as some  
748 uncontrolled and/or unintended events (e.g., chasing the animal before the tail suspension  
749 test) may have occurred during that period. The baseline signal was calculated as the  
750 average  $\Delta F/F$  100 s prior to the start of the behavioral test. The peak response after each  
751 drug injection was calculated as the average maximum  $\Delta F/F$  during all tail suspension trials.  
752 The decay time was calculated as the average time required to reach half of the peak  
753 response.

754 Except where indicated otherwise, group differences were analyzed using the Student's *t*-  
755 test, Wilcoxon matched-pairs signed rank test, Shapiro-Wilk normality test, one-way  
756 ANOVA test, or Friedman's test. Except where indicated otherwise, all summary data are  
757 presented as the mean  $\pm$  SEM.

758

759 **Data and software availability**

760 The custom MATLAB programs using in this study will be provided upon request to the  
761 corresponding author.

762

763

764 **References**

- 765 Akerboom, J., Chen, T.-W., Wardill, T.J., Tian, L., Marvin, J.S., Mutlu, S., Calderón, N.C., Esposti, F.,  
766 Borghuis, B.G., Sun, X.R., *et al.* (2012). Optimization of a GCaMP Calcium Indicator for Neural  
767 Activity Imaging. *The Journal of Neuroscience* *32*, 13819.
- 768 Bast, N., Poustka, L., and Freitag, C.M. (2018). The locus coeruleus-norepinephrine system as  
769 pacemaker of attention - a developmental mechanism of derailed attentional function in autism  
770 spectrum disorder. *Eur J Neurosci* *47*, 115-125.
- 771 Berridge, C.W., Schmeichel, B.E., and Espana, R.A. (2012). Noradrenergic modulation of  
772 wakefulness/arousal. *Sleep Med Rev* *16*, 187-197.
- 773 Berridge, C.W., and Spencer, R.C. (2016). Differential cognitive actions of norepinephrine  $\alpha_2$  and  
774  $\alpha_1$  receptor signaling in the prefrontal cortex. *Brain Res* *1641*, 189-196.
- 775 Berridge, C.W., and Waterhouse, B.D. (2003). The locus coeruleus-noradrenergic system:  
776 modulation of behavioral state and state-dependent cognitive processes. *Brain Research Reviews*  
777 *42*, 33-84.
- 778 Bito, L., Davson, H., Levin, E., Murray, M., and Snider, N. (1966). THE CONCENTRATIONS OF FREE  
779 AMINO ACIDS AND OTHER ELECTROLYTES IN CEREBROSPINAL FLUID, IN VIVO DIALYSATE OF  
780 BRAIN, AND BLOOD PLASMA OF THE DOG\*. *Journal of Neurochemistry* *13*, 1057-1067.
- 781 Brodde, O.-E., Bruck, H., Leineweber, K., and Seyfarth, T. (2001). Presence, distribution and  
782 physiological function of adrenergic and muscarinic receptor subtypes in the human heart. *Basic*  
783 *Research in Cardiology* *96*, 528-538.
- 784 Bruns, D. (2004). Detection of transmitter release with carbon fiber electrodes. *Methods* *33*, 312-  
785 321.
- 786 Chefer, V.I., Thompson, A.C., Zapata, A., and Shippenberg, T.S. (2009). Overview of Brain  
787 Microdialysis. *Current Protocols in Neuroscience* *47*, 7.1.1-7.1.28.
- 788 Chrousos, G.P. (2009). Stress and disorders of the stress system. *Nat Rev Endocrinol* *5*, 374-381.
- 789 Chung, K.Y., Rasmussen, S.G., Liu, T., Li, S., DeVree, B.T., Chae, P.S., Calinski, D., Kobilka, B.K., Woods,  
790 V.L., Jr., and Sunahara, R.K. (2011). Conformational changes in the G protein Gs induced by the  
791 beta2 adrenergic receptor. *Nature* *477*, 611-615.
- 792 Espay, A.J., LeWitt, P.A., and Kaufmann, H. (2014). Norepinephrine deficiency in Parkinson's disease:  
793 the case for noradrenergic enhancement. *Mov Disord* *29*, 1710-1719.
- 794 Falkner, A.L., Grosenick, L., Davidson, T.J., Deisseroth, K., and Lin, D. (2016). Hypothalamic control  
795 of male aggression-seeking behavior. *Nature Neuroscience* *19*, 596.
- 796 Fenno, L., Yizhar, O., and Deisseroth, K. (2011). The development and application of optogenetics.  
797 *Annu Rev Neurosci* *34*, 389-412.
- 798 Goddard, A.W., Ball, S.G., Martinez, J., Robinson, M.J., Yang, C.R., Russell, J.M., and Shekhar, A.  
799 (2010). Current perspectives of the roles of the central norepinephrine system in anxiety and  
800 depression. *Depress Anxiety* *27*, 339-350.
- 801 Hashikawa, K., Hashikawa, Y., Falkner, A., and Lin, D. (2016). The neural circuits of mating and  
802 fighting in male mice. *Current opinion in neurobiology* *38*, 27-37.
- 803 Inoue, A., Ishiguro, J., Kitamura, H., Arima, N., Okutani, M., Shuto, A., Higashiyama, S., Ohwada, T.,  
804 Arai, H., Makide, K., *et al.* (2012). TGF $\alpha$  shedding assay: an accurate and versatile method for  
805 detecting GPCR activation. *Nature Methods* *9*, 1021.
- 806 Jing, M., Zhang, P., Wang, G., Feng, J., Mesik, L., Zeng, J., Jiang, H., Wang, S., Looby, J.C., Guagliardo,  
807 N.A., *et al.* (2018). A genetically encoded fluorescent acetylcholine indicator for in vitro and in vivo



808 studies. *Nature Biotechnology* *36*, 726.

809 Justice, J.B. (1993). Quantitative microdialysis of neurotransmitters. *Journal of Neuroscience*  
810 *Methods* *48*, 263-276.

811 Kroeze, W.K., Sassano, M.F., Huang, X.-P., Lansu, K., McCorvy, J.D., Giguère, P.M., Sciaky, N., and  
812 Roth, B.L. (2015). PRESTO-Tango as an open-source resource for interrogation of the druggable  
813 human GPCRs. *Nature Structural & Molecular Biology* *22*, 362.

814 Lee, G.J., Park, J.H., and Park, H.K. (2008). Microdialysis applications in neuroscience. *Neurological*  
815 *Research* *30*, 661-668.

816 Leibowitz, S.F. (1970). Reciprocal Hunger-Regulating Circuits Involving Alpha- and Beta-  
817 Adrenergic Receptors Located, Respectively, in the Ventromedial and Lateral Hypothalamus.  
818 *Proceedings of the National Academy of Sciences of the United States of America* *67*, 1063-1070.

819 Leibowitz, S.F., Jhanwar-Uniyal, M., Dvorkin, B., and Makman, M.H. (1982). Distribution of  $\alpha$ -  
820 adrenergic,  $\beta$ -adrenergic and dopaminergic receptors in discrete hypothalamic areas of rat. *Brain*  
821 *Research* *233*, 97-114.

822 Li, L., Feng, X., Zhou, Z., Zhang, H., Shi, Q., Lei, Z., Shen, P., Yang, Q., Zhao, B., Chen, S., *et al.* (2018).  
823 Stress Accelerates Defensive Responses to Looming in Mice and Involves a Locus Coeruleus-  
824 Superior Colliculus Projection. *Curr Biol* *28*, 859-871 e855.

825 Manglik, A., Kim, T.H., Masureel, M., Altenbach, C., Yang, Z., Hilger, D., Lerch, M.T., Kobilka, T.S.,  
826 Thian, F.S., Hubbell, W.L., *et al.* (2015). Structural Insights into the Dynamic Process of beta2-  
827 Adrenergic Receptor Signaling. *Cell* *161*, 1101-1111.

828 Marien, M.R., Colpaert, F.C., and Rosenquist, A.C. (2004). Noradrenergic mechanisms in  
829 neurodegenerative diseases: a theory. *Brain Research Reviews* *45*, 38-78.

830 Marvin, J.S., Borghuis, B.G., Tian, L., Cichon, J., Harnett, M.T., Akerboom, J., Gordus, A., Renninger,  
831 S.L., Chen, T.W., Bargmann, C.I., *et al.* (2013). An optimized fluorescent probe for visualizing  
832 glutamate neurotransmission. *Nat Methods* *10*, 162-170.

833 McQuade, R., and Stanford, S.C. (2000). A microdialysis study of the noradrenergic response in rat  
834 frontal cortex and hypothalamus to a conditioned cue for aversive, naturalistic environmental  
835 stimuli. *Psychopharmacology* *148*, 201-208.

836 Meng, C., Zhou, J., Papaneri, A., Peddada, T., Xu, K., and Cui, G. (2018). Spectrally Resolved Fiber  
837 Photometry for Multi-component Analysis of Brain Circuits. *Neuron* *98*, 707-717.e704.

838 Moore, R.Y., and Bloom, F.E. (1979). Central Catecholamine Neuron Systems: Anatomy and  
839 Physiology of the Norepinephrine and Epinephrine Systems. *Annual Review of Neuroscience* *2*,  
840 113-168.

841 Moret, C., and Briley, M. (2011). The importance of norepinephrine in depression. *Neuropsychiatr*  
842 *Dis Treat* *7*, 9-13.

843 Muller, A., Joseph, V., Slesinger, P.A., and Kleinfeld, D. (2014). Cell-based reporters reveal in vivo  
844 dynamics of dopamine and norepinephrine release in murine cortex. *Nature Methods* *11*, 1245.

845 Nakanishi, J., Takarada, T., Yunoki, S., Kikuchi, Y., and Maeda, M. (2006). FRET-based monitoring  
846 of conformational change of the  $\beta_2$  adrenergic receptor in living cells. *Biochemical and Biophysical*  
847 *Research Communications* *343*, 1191-1196.

848 Nygaard, R., Zou, Y., Dror, R.O., Mildorf, T.J., Arlow, D.H., Manglik, A., Pan, A.C., Liu, C.W., Fung, J.J.,  
849 Bokoch, M.P., *et al.* (2013). The dynamic process of beta(2)-adrenergic receptor activation. *Cell*  
850 *152*, 532-542.

851 Olive, M.F., Mehmert, K.K., and Hodge, C.W. (2000). Microdialysis in the mouse nucleus accumbens:

852 a method for detection of monoamine and amino acid neurotransmitters with simultaneous  
853 assessment of locomotor activity. *Brain Research Protocols* *5*, 16-24.

854 Pacak, K., Palkovits, M., Kopin, I.J., and Goldstein, D.S. (1995). Stress-Induced Norepinephrine  
855 Release in the Hypothalamic Paraventricular Nucleus and Pituitary-Adrenocortical and  
856 Sympathoadrenal Activity: In Vivo Microdialysis Studies. *Frontiers in Neuroendocrinology* *16*, 89-  
857 150.

858 Park, J., Kile, B.M., and Mark Wightman, R. (2009). In vivo voltammetric monitoring of  
859 norepinephrine release in the rat ventral bed nucleus of the stria terminalis and anteroventral  
860 thalamic nucleus. *European Journal of Neuroscience* *30*, 2121-2133.

861 Patriarchi, T., Cho, J.R., Merten, K., Howe, M.W., Marley, A., Xiong, W.-H., Folk, R.W., Broussard, G.J.,  
862 Liang, R., Jang, M.J., *et al.* (2018). Ultrafast neuronal imaging of dopamine dynamics with designed  
863 genetically encoded sensors. *Science* *360*.

864 Rasmussen, S.G., Choi, H.J., Fung, J.J., Pardon, E., Casarosa, P., Chae, P.S., Devree, B.T., Rosenbaum,  
865 D.M., Thian, F.S., Kobilka, T.S., *et al.* (2011a). Structure of a nanobody-stabilized active state of the  
866 beta(2) adrenoceptor. *Nature* *469*, 175-180.

867 Rasmussen, S.G., DeVree, B.T., Zou, Y., Kruse, A.C., Chung, K.Y., Kobilka, T.S., Thian, F.S., Chae, P.S.,  
868 Pardon, E., Calinski, D., *et al.* (2011b). Crystal structure of the beta2 adrenergic receptor-Gs protein  
869 complex. *Nature* *477*, 549-555.

870 Ren, Q., Kurose, H., Lefkowitz, R.J., and Cotecchia, S. (1993). Constitutively active mutants of the  
871 alpha 2-adrenergic receptor. *Journal of Biological Chemistry* *268*, 16483-16487.

872 Robinson, D.L., Hermans, A., Seipel, A.T., and Wightman, R.M. (2008). Monitoring Rapid Chemical  
873 Communication in the Brain. *Chemical Reviews* *108*, 2554-2584.

874 Robinson, D.L., Venton, B.J., Heien, M.L.A.V., and Wightman, R.M. (2003). Detecting Subsecond  
875 Dopamine Release with Fast-Scan Cyclic Voltammetry in Vivo. *Clinical Chemistry* *49*, 1763.

876 Schwarz, L.A., and Luo, L. (2015). Organization of the Locus Coeruleus-Norepinephrine System.  
877 *Current Biology* *25*, R1051-R1056.

878 Schwarz, L.A., Miyamichi, K., Gao, X.J., Beier, K.T., Weissbourd, B., DeLoach, K.E., Ren, J., Ibanes, S.,  
879 Malenka, R.C., Kremer, E.J., *et al.* (2015). Viral-genetic tracing of the input-output organization of  
880 a central noradrenaline circuit. *Nature* *524*, 88.

881 Shekhar, A., Katner, J.S., Sajdyk, T.J., and Kohl, R.R. (2002). Role of norepinephrine in the  
882 dorsomedial hypothalamic panic response: An in vivo microdialysis study. *Pharmacology*  
883 *Biochemistry and Behavior* *71*, 493-500.

884 Singleman, C., and Holtzman, N.G. (2014). Growth and Maturation in the Zebrafish, *Danio Rerio*: A  
885 Staging Tool for Teaching and Research. *Zebrafish* *11*, 396-406.

886 Sokolowski, K., and Corbin, J.G. (2012). Wired for behaviors: from development to function of  
887 innate limbic system circuitry. *Frontiers in Molecular Neuroscience* *5*, 55.

888 Sun, F., Zeng, J., Jing, M., Zhou, J., Feng, J., Owen, S.F., Luo, Y., Li, F., Wang, H., Yamaguchi, T., *et al.*  
889 (2018). A Genetically Encoded Fluorescent Sensor Enables Rapid and Specific Detection of  
890 Dopamine in Flies, Fish, and Mice. *Cell* *174*, 481-496.e419.

891 Tanaka, M. (1999). Emotional Stress and Characteristics of Brain Noradrenaline Release in the Rat.  
892 *INDUSTRIAL HEALTH* *37*, 143-156.

893 Urban, D.J., and Roth, B.L. (2015). DREADDs (designer receptors exclusively activated by designer  
894 drugs): chemogenetic tools with therapeutic utility. *Annu Rev Pharmacol Toxicol* *55*, 399-417.

895 Vilardaga, J.-P., Bünemann, M., Krasel, C., Castro, M., and Lohse, M.J. (2003). Measurement of the

896 millisecond activation switch of G protein-coupled receptors in living cells. *Nature Biotechnology*  
897 *21*, 807.

898 Wan, Q., Okashah, N., Inoue, A., Nehmé, R., Carpenter, B., Tate, C.G., and Lambert, N.A. (2018).  
899 Mini G protein probes for active G protein-coupled receptors (GPCRs) in live cells. *Journal of*  
900 *Biological Chemistry*.

901 Wang, A., Feng, J., Li, Y., and Zou, P. (2018a). Beyond Fluorescent Proteins: Hybrid and  
902 Bioluminescent Indicators for Imaging Neural Activities. *ACS Chemical Neuroscience* *9*, 639-650.

903 Wang, H., Jing, M., and Li, Y. (2018b). Lighting up the brain: genetically encoded fluorescent  
904 sensors for imaging neurotransmitters and neuromodulators. *Curr Opin Neurobiol* *50*, 171-178.

905 Watson, C.J., Venton, B.J., and Kennedy, R.T. (2006). In Vivo Measurements of Neurotransmitters  
906 by Microdialysis Sampling. *Analytical Chemistry* *78*, 1391-1399.

907 Yang, T., and Shah, N.M. (2016). Molecular and neural control of sexually dimorphic social  
908 behaviors. *Current Opinion in Neurobiology* *38*, 89-95.

909 Yao, Y., Li, X., Zhang, B., Yin, C., Liu, Y., Chen, W., Zeng, S., and Du, J. (2016). Visual Cue-  
910 Discriminative Dopaminergic Control of Visuomotor Transformation and Behavior Selection.  
911 *Neuron* *89*, 598-612.

912 Zhao, Y., Araki, S., Wu, J., Teramoto, T., Chang, Y.-F., Nakano, M., Abdelfattah, A.S., Fujiwara, M.,  
913 Ishihara, T., Nagai, T., *et al.* (2011). An Expanded Palette of Genetically Encoded Ca(2+) Indicators.  
914 *Science (New York, NY)* *333*, 1888-1891.

915 Zhou, Z., and Mislér, S. (1995). Amperometric detection of stimulus-induced quantal release of  
916 catecholamines from cultured superior cervical ganglion neurons. *Proceedings of the National*  
917 *Academy of Sciences* *92*, 6938.

918 Zimmerman, B.G. (1981). Adrenergic Facilitation by Angiotensin: Does it Serve a Physiological  
919 Function? *Clinical Science* *60*, 343.

920 Zou, P., Zhao, Y., Douglass, A.D., Hochbaum, D.R., Brinks, D., Werley, C.A., Harrison, D.J., Campbell,  
921 R.E., and Cohen, A.E. (2014). Bright and fast multicoloured voltage reporters via electrochromic  
922 FRET. *Nat Commun* *5*, 4625.

923

924

925 **Figure 1. Design and optimization of genetically encoded NE sensors.**

926 **(A)** Selection of a candidate sensor scaffold by screening several NE-binding GPCRs.  
927 Shown at the right are example images of the indicated chimeric GPCR-cpEGFP  
928 candidates expressed in HEK293T cells. Yellow arrows indicate robust membrane  
929 trafficking, and red arrows indicate impaired membrane trafficking. See also Figure S1.

930 **(B)** Identification of the most responsive NE sensor, NE0.5m (indicated by the black square)  
931 by screening the cpEGFP insertion site in ICL3 of the  $\alpha$ 2AR.  $\Delta F/F_0$  refers to the peak  
932 change in fluorescence intensity in response to 100  $\mu$ M NE.

933 **(C)** Optimizing the GRAB<sub>NE</sub> sensors by mutational screening of the insertion linker. NE0.5m  
934 was used as a template, and the indicated amino acids on N-terminal and C-terminal sides  
935 of the cpEGFP insert were mutated individually. Sensor NE1m (indicated by the pink  
936 squares) was identified due to having the strongest response ( $\Delta F/F_0$ ) and brightness  
937 relative to the original NE0.5m sensor (indicated by the dashed line at 1.0).

938 **(D)** Tuning the sensor's affinity for NE by introducing mutations in the GPCR. Magnified  
939 views of the ligand-binding pocket view from the cytosol are shown; key residues involved  
940 in ligand binding and inducing a conformational change upon ligand binding are indicated.  
941 The middle panel shows example images of HEK293T cells expressing the indicated  
942 GRAB<sub>NE</sub> sensors; EGFP fluorescence is shown in the left column, and the fluorescence  
943 response in the presence of 100  $\mu$ M NE is shown in the right column. Shown at the right  
944 are the normalized dose-response curves for the three GRAB<sub>NE</sub> sensors, with  $C_{50}$  values  
945 (top), and the average fluorescence change in response to 100  $\mu$ M NE (bottom); n = 21-  
946 67 cells from 3-5 cultures for each sensor.

947 The scale bars in (A) and (D) represent 10  $\mu$ m.

948 \*\*\* $p < 0.001$  (Student's *t*-test).

949

950 **Figure 2. Characterization of GRAB<sub>NE</sub> sensors in cultured cells.**

951 **(A-C)** HEK293T cells were loaded with NPEC-NE, which was uncaged by photolysis with  
952 a pulse of 405-nm light. Uncaging caused a rapid increase in GRAB<sub>NE1h</sub> fluorescence,  
953 which was blocked in the presence of 10  $\mu$ M yohimbine (YO). The data in A represent 3  
954 trials each, and the data in C represent 7 cells from 3 cultures. The white dotted square  
955 indicates the image region and the purple square indicates the illumination region.

956 **(D-F)** NE was applied to HEK293T cells expressing GRAB<sub>NE1m</sub> or GRAB<sub>NE1h</sub> to measure  
957  $T_{on}$ . Yohimbine (YO) was then applied in order to measure  $T_{off}$ ; The white dotted line  
958 indicates the line-scanning region.  $n \geq 6$  cells from 6 cultures.

959 **(G)** The indicated compounds were applied to GRAB<sub>NE1m</sub> and GRAB<sub>NE1h</sub>, and the change  
960 in fluorescence relative to NE is plotted.

961 **(H)** Dose-response curves for GRAB<sub>NE1m</sub>, GRAB<sub>NE1h</sub>, and wild-type  $\alpha$ 2AR for NE and DA,  
962 with  $EC_{50}$  values shown;  $n \geq 3$  wells with 100-300 cells each.

963 **(I)** Fast-scan cyclic voltammetry measurements in response to increasing concentrations  
964 of NE and DA. The insets show exemplar cyclic voltammograms of NE and DA at 100  $\mu$ M,  
965 with peak current occurring at  $\sim 0.6$  V.

966 **(J)** Time course of  $\Delta F/F_0$  for GRAB<sub>NE</sub> sensors measured over a 2-h time frame; note that  
967 the fluorescent signal remained at the cell surface even after 180 min, indicating no  
968 measurable internalization or desensitization.  $n = 3$  wells with 100-300 cells each.

969 **(K)** A TANGO assay was performed in order to measure  $\beta$ -arrestin-mediated signaling by  
970 GRAB<sub>NE1m</sub>, GRAB<sub>NE1h</sub>, and wild-type  $\alpha$ 2AR in the presence of increasing concentrations  
971 of NE;  $n = 4$  wells with  $\geq 10^5$  cells each.

972 **(L,M)** GRAB<sub>NE</sub> sensors do not couple to downstream G protein signaling pathways. Wild-  
973 type  $\alpha$ 2AR, but not GRAB<sub>NE1m</sub> or GRAB<sub>NE1h</sub>, drives  $G_{ai}$  signaling measured using a  
974 luciferase complementation assay (L). Disrupting of G protein activation with pertussis  
975 toxin does not affect the NE-induced fluorescence change in GRAB<sub>NE1m</sub> or GRAB<sub>NE1h</sub> (M).  
976  $n = 3$  wells with  $\geq 10^5$  cells each.

977 The scale bars in (A), (D), and (J) represent 10  $\mu$ m.

978 \* $p < 0.05$ , \*\* $p < 0.01$ , and \*\*\* $p < 0.001$ ; n.s., not significant (Student's  $t$ -test).

979

980 **Figure 3. Characterization of GRAB<sub>NE</sub> sensors in cultured neurons.**

981 **(A-C)** GRAB<sub>NE1m</sub> is expressed in various plasma membrane compartment of cultured  
982 neurons. Cultured cortical neurons were co-transfected with GRAB<sub>NE1m</sub> and RFP-CAAX to  
983 label the plasma membrane, and the fluorescence response induced by bath application  
984 of NE was measured in the cell body, dendritic shaft and spine, and axon **(C)**.  $n > 10$   
985 neurons from 4 cultures.

986 **(D,E)** Cultured cortical neurons expressing GRAB<sub>NE1m</sub> and GRAB<sub>NE1h</sub>, but not GRAB<sub>NEmut</sub>,  
987 respond to application of NE (10  $\mu$ M). EGFP fluorescence and pseudocolor images  
988 depicting the response to NE are shown in **(D)**, and the time course and summary of peak  
989  $\Delta F/F_0$  are shown in **(E)**.  $n > 15$  neurons from 3 cultures.

990 **(F)** Dose-response curve for GRAB<sub>NE</sub> sensors expressed in cultured cortical neurons in  
991 response to NE and DA.  $n > 10$  neurons from 3 cultures.

992 **(G)** Example trace (top) and summary (bottom) of cultured neurons transfected with  
993 GRAB<sub>NE1m</sub> and treated with the indicated compounds at 10  $\mu$ M each.  $n = 9$  neurons from  
994 3 cultures.

995 **(H,I)** The fluorescence change in GRAB<sub>NE1m</sub> induced by 100  $\mu$ M NE is stable for up to 1 h.  
996 Representative images taken at the indicated times are shown in **(H)**. An example trace  
997 and summary data are shown in **(I)**. Where indicated, 10  $\mu$ M yohimbine (YO) was added.  
998  $n = 11$  neurons from 3 cultures.

999 The scale bars in **(A)** and **(B)** represent 10  $\mu$ m; the scale bars in **(D)** and **(H)** represent 25  
1000  $\mu$ m.

1001 \*\*\* $p < 0.001$ ; n.s., not significant (Student's  $t$ -test).

1002 **Figure 4. Release of endogenous NE measured in mouse brain slices.**

1003 **(A) Left**, schematic illustration of the slice experiments. An AAV expressing hSyn-NE1m  
1004 was injected into the LC; two weeks later, acute brain slices were prepared and used for  
1005 electric stimulation experiments. **Right**, exemplar 2-photon microscopy images showing  
1006 the distribution of GRAB<sub>NE1m</sub> in the plasma membrane of LC neurons.

1007 **(B) Left and middle**, representative pseudocolor images and corresponding fluorescence  
1008 changes in GRAB<sub>NE1m</sub>-expressing neurons in response to 2, 20, and 100 pulses delivered  
1009 at 20 Hz. The ROI (50- $\mu$ m diameter) for data analysis is indicated in the images. **Right**,  
1010 summary of the peak fluorescence change in slices stimulated as indicated; n = 5 slices  
1011 from 5 mice.

1012 **(C)** Exemplar traces and summary data of GRAB<sub>NE1m</sub>-expressing neurons in response to  
1013 20 electrical stimuli delivered at 20 Hz in ACSF, 4-AP (100  $\mu$ M), or 4-AP with Cd<sup>2+</sup> (100 $\mu$ M);  
1014 n = 4 slices from 4 mice.

1015 **(D)** Kinetic properties of the electrically evoked fluorescence responses in GRAB<sub>NE1m</sub>-  
1016 expressing LC neurons. **Left**, image showing a GRAB<sub>NE1m</sub>-expressing LC neuron for line  
1017 scan analysis (red dashed line). **Middle and right**, example trace and summary of the  
1018 responses elicited in GRAB<sub>NE1m</sub>-expressing neurons before, and after 10 pulses delivered  
1019 at 100Hz; n = 4 slices from 4 mice.

1020 **(E)** The norepinephrine transporter blocker desipramine (Desi, 10  $\mu$ M; red) increases the  
1021 effect of electrical stimuli (20 pulses at 20 Hz) or two trains of stimuli with a 1-s interval  
1022 compared to ACSF (black traces). n = 5 slices from 5 mice.

1023 **(F)** The fluorescence response in GRAB<sub>NE1m</sub>-expressing neurons is stable. Eight stimuli  
1024 (20 pulses at 20 Hz) were applied at 5-min intervals, and the response (normalized to the  
1025 first train) is plotted against time. n = 5 slices from 5 mice.

1026 **(G)** Traces and summary data of the fluorescence response measured in neurons  
1027 expressing GRAB<sub>NE1m</sub>, GRAB<sub>NEmut</sub>, or GRAB<sub>DA1m</sub> in response to 20 pulses delivered at 20  
1028 Hz in the presence of ACSF or 20  $\mu$ M YO; n = 3-7 slices from 3-7 mice.

1029 **(H)** Traces and summary data of the fluorescence response measured in neurons  
1030 expressing GRAB<sub>NE1m</sub> or GRAB<sub>DA1m</sub>. Where indicated, 50  $\mu$ M NE, 50  $\mu$ M DA, 20  $\mu$ M  
1031 yohimbine (YO), and/or 20  $\mu$ M haloperidol (Halo) was applied to the cells. n = 3-5 slices  
1032 from 3-5 mice.

1033 The scale bars represent 10  $\mu$ m.

1034 \* $p$  < 0.05, \*\* $p$  < 0.01, and \*\*\* $p$  < 0.001; n.s., not significant (Student's  $t$ -test).

1035

1036 **Figure 5. GRAB<sub>NE1m</sub> can be used to measure noradrenergic activity *in vivo* in**  
1037 **transgenic zebrafish.**

1038 **(A)** *In vivo* confocal image of a Tg(HuC:GRAB<sub>NE1m</sub>) zebrafish expressing GRAB<sub>NE1m</sub> in  
1039 neurons driven by the HuC promoter. Larvae at 6 days post-fertilization were used.

1040 **(B-D)** Bath application of NE (50  $\mu$ M) but not DA (50  $\mu$ M) elicits a significant increase in  
1041 fluorescence in the tectal neuropil of Tg(HuC:GRAB<sub>NE1m</sub>) zebrafish, but not in GRAB<sub>NEmut</sub>  
1042 zebrafish, and this increase is blocked by YO (50  $\mu$ M), but not ICI 118,551 (50  $\mu$ M). n = 7.

1043 **(E-H)** Visual looming stimuli evoke the release of endogenous NE in the midbrain of  
1044 GRAB<sub>NE1m</sub> zebrafish, but not in GRAB<sub>NEmut</sub> zebrafish. The looming stimuli paradigm is  
1045 shown in the left of **(E)**. Where indicated, YO (50  $\mu$ M) or ICI 118,551 (50  $\mu$ M) was  
1046 applied. Desipramine (Desi, 50  $\mu$ M) application slowed the decay of looming-induced NE  
1047 release **(H)**. n = 6 for GRAB<sub>NEmut</sub> and n = 9 for the others.

1048 **(I-K)** Single-cell labeling of GRAB<sub>NE1m</sub> in the midbrain of zebrafish larva **(I)**, with looming-  
1049 evoked responses shown in **(I and J)**. The summary data for 6 labeled cells are shown in  
1050 **(K)**.

1051 The scale bar shown in **(A, left)** represents 10  $\mu$ m; the scale bars shown in **(A, right)**, **(B)**  
1052 and **(E)** represent 50  $\mu$ m. The scale bar shown in **(I)** represents 5  $\mu$ m.

1053 \* $p$  < 0.05, \*\* $p$  < 0.01, \*\*\* $p$  < 0.001, and \*\*\*\* $p$  < 0.0001; n.s., not significant (Wilcoxon  
1054 matched-pairs signed rank test in panel **H**, all others were analyzed using the paired or  
1055 unpaired Student's *t*-test).

1056



1057 **Figure 6. GRAB<sub>NE1m</sub> can be used to measure optogenetically stimulated**  
1058 **noradrenergic activity *in vivo* in freely moving mice.**

1059 **(A)** Schematic illustration depicting the experimental design for recording GRAB<sub>NE1m</sub> and  
1060 GRAB<sub>NEmut</sub> fluorescence in response to optical stimulation of C1V1 in the locus coeruleus  
1061 (LC).

1062 **(B)** Representative traces of optogenetically stimulated GRAB<sub>NE1m</sub> (top) and GRAB<sub>NEmut</sub>  
1063 (bottom) activity in the LC before (baseline, left), 15 min after an i.p. injection of the NET  
1064 blocker desipramine (10 mg/kg, middle), and 15 min after an i.p. injection of the  $\alpha$ 2AR  
1065 antagonist yohimbine (2 mg/kg, right). The vertical tick marks indicate the optogenetic  
1066 stimuli. Black arrows represent the timing for grabbing and i.p. injection.

1067 **(C-D)** Average traces of GRAB<sub>NE1m</sub> fluorescence (**C**), summary data (**D**), and the decay  
1068 time constant (**E**) in response to optical stimulation in the LC following treatment with the  
1069 indicated compounds. n = 15 trials from 3 mice for each condition.

1070 **(F,G)** Schematic illustration (**F, left**), representative traces (**F, right**), average  
1071 fluorescence change (**G, left**), and summary data (**G, right**) for GRAB<sub>NE1m</sub> in response to  
1072 optical stimulation of noradrenergic neurons in the LC and dopaminergic neurons in the  
1073 SNc.

1074 \*\*\* $p < 0.001$  (for D and E, One-Way ANOVA, for G, Student's  $t$ -test).

1075

1076

1077 **Figure 7. GRAB<sub>NE1m</sub> can be used to measure noradrenergic activity in the**  
1078 **hypothalamus during stress, food-related behavior, and social interaction.**

1079 **(A)** Schematic diagrams depicting the fiber photometry recording, virus injection, and  
1080 recording sites.

1081 **(B)** Histology showing the expression of GRAB<sub>NE1m</sub> (green) and placement of the  
1082 recording; the nuclei were counterstained with DAPI (blue). Scale bar: 500µm.

1083 **(C1-E6)** Representative traces **(C1-C6)**, average per-stimulus histograms **(D1-D6)**, and  
1084 summary data **(E1-E6)** showing normalized GRAB<sub>NE1m</sub> fluorescence ( $\Delta F/F$ ) before and  
1085 during the forced swim test **(1)**, the tail suspension test **(2)**, the hand presentation test  
1086 **(3)**, social interaction with an intruder of the opposite sex **(4)** and the same sex **(5)**, and  
1087 presentation of peanut butter **(6)**. n = 3 animals each.

1088 **(F)** Representative traces of GRAB<sub>NE1m</sub> fluorescence during the tail suspension test 10  
1089 minutes after saline injection, 25 minutes after atomoxetine (ATX) or yohimbine (YO)  
1090 injection, and 15 minutes after GBR 12909 or sulpiride (Sul) injection.

1091 **(G-I)** Average peri-stimulus histograms **(H)**, peak change in GRAB<sub>NE1m</sub> fluorescence, and  
1092 post-test decay time measured during the tail suspension test after injection of the  
1093 indicated compounds. n = 3 each.

1094 The Shapiro-Wilk normality test was performed; if the test revealed that the followed a  
1095 normal distribution, a paired Student's *t*-test or one-way repeated measures ANOVA  
1096 followed by Tukey's multiple comparisons was performed. If the values did not follow a  
1097 normal distribution, a non-parametric ANOVA (Friedman's test) was performed followed  
1098 by Dunn's multiple comparisons test. In **(C)** and **(D)**, the blue dotted lines represent the  
1099 start of the stimulus, and the red dotted lines represent the end of the trial.

1100 \**p* < 0.05 and \*\**p* < 0.01.

1101

1102 **Figure S1. Characterization of the membrane trafficking of a panel of screening**  
1103 **candidates (related to Fig. 1).**

1104 Representative images (**A**) of HEK293T cells co-transfected with the indicated screening  
1105 candidates (green) together with RFP-CAAX (red) to label the plasma membrane. KDELR-  
1106 EGFP was used as an ER marker. The dashed white lines indicate the line used for the  
1107 line-scanning data shown in (**B**) and summarized in

1108 (**C**)  $n = 30$  cells from 4-5 cultures.

1109 The scale bars in (**A**) represent  $10\ \mu\text{m}$ .

1110  $*p < 0.05$  and  $***p < 0.001$ ; n.s., not significant (Student's  $t$ -test).

1111

1112 **Figure S2. Further characterization of GRAB<sub>NE</sub> sensors (related to Fig. 2).**

1113 **(A)** Fluorescence intensity of GRAB<sub>NE1m</sub> and GRAB<sub>NE1h</sub> expressed relative to EGFP- $\alpha$ 2AR.  
1114  $n \geq 2$  wells with 300-500 cells per well.

1115 **(B)** G protein activation mediated by GRAB<sub>NE1m</sub> and wild-type  $\alpha$ 2AR was measured using  
1116 the TGF $\alpha$  shedding assay and is expressed relative to  $\alpha$ 2AR.  $n = 4$  wells with  $\geq 10^5$  cells  
1117 per well.

1118 **(C)** Exemplar **(left)** and summary data **(right)** showing the photostability of GRAB<sub>NE</sub>  
1119 sensors and EGFP-CAAX using confocal **(top)** and 2-photon **(bottom)** microscopy.  $n > 10$   
1120 cells from at least 3 cultures.

1121 **(D)** Exemplar cyclic voltammograms for 10  $\mu$ M NE **(top)**, 10  $\mu$ M DA **(middle)**, and 10  $\mu$ M  
1122 Glu **(bottom)** measured using FSCV are shown. The traces were averaged from separate  
1123 200 trials.

1124 \*\*\* $p < 0.001$  (Student's  $t$ -test).

1125

1126 **Figure S3. GRAB<sub>NE</sub> sensors respond selectively to noradrenergic agonists in brain**  
1127 **lices (related to Fig. 4).**

1128 **(A)** Schematic drawing showing the experimental design for measuring CA1 pyramidal  
1129 neurons in cultured rat hippocampal slices.

1130 **(B)** Heat-map images of the change in fluorescence in GRAB<sub>NE1m</sub>-expressing CA1 neurons  
1131 in response to a 10-ms local application of NE (20  $\mu$ M). The red and orange traces show  
1132 the fluorescence responses of two neurons, and the green trace shows the average  
1133 response of all neurons in the field. The scale represents 20  $\mu$ m.

1134 **(C)** Fluorescence responses measured in GRAB<sub>NE1m</sub><sup>-</sup>, GRAB<sub>NE1h</sub><sup>-</sup>, and GRAB<sub>NEmut</sub><sup>-</sup>  
1135 expressing CA1 neurons following a 10-ms puff (arrow) of ACSF, NE (20  $\mu$ M), Epi (100  
1136  $\mu$ M), or brimonidine (UK, 20  $\mu$ M).

1137 **(D)** Maximum  $\Delta F/F_0$  response measured in GRAB<sub>NE1m</sub><sup>-</sup>, GRAB<sub>NE1h</sub><sup>-</sup>, and GRAB<sub>NEmut</sub><sup>-</sup>  
1138 expressing CA1 neurons following a 10-ms puff of ACSF or NE. n = 20-21 cells from 8  
1139 animals per group.

1140 **(E)** Rise times and decay time constants were measured in CA1 neurons expressing  
1141 GRAB<sub>NE1m</sub><sup>-</sup> and GRAB<sub>NE1h</sub><sup>-</sup> expressing CA1 neurons in response to a puff of NE. n = 21  
1142 cells from 8 animals.

1143 **(F)** Maximum  $\Delta F/F_0$  response measured in GRAB<sub>NE1m</sub><sup>-</sup>-expressing CA1 neurons following  
1144 a puff of NE, Epi, or brimonidine (UK). n = 20-21 cells from 8 animals per group.

1145 **(G)** Rise times and decay time constants were measured in GRAB<sub>NE1m</sub><sup>-</sup>-expressing CA1  
1146 neurons following a puffs of Epi or brimonidine (UK).

1147 **(H)** Schematic illustration depicting AAV-mediated delivery of GRAB<sub>NE1h</sub> in the mouse  
1148 hippocampus and bath application of various agonists in the dentate gyrus.

1149 **(I)** Example images showing GRAB<sub>NE1h</sub> (green) expression and dopamine beta  
1150 hydroxylase (DBH) immunostaining (red) in the dentate gyrus of AAV-GRAB<sub>NE1h</sub><sup>-</sup> and  
1151 control-injected hippocampi. The nuclei were counterstained with DAPI. The scale bar  
1152 represents 100  $\mu$ m.

1153 **(J)** Electrical stimulation evokes NE release in the hippocampus measured as a change in  
1154 GRAB<sub>NE1h</sub> fluorescence. The response was blocked by bath application of yohimbine  
1155 (YO). Exemplar images (**left**), representative traces (**middle**), and the summary data (**right**)  
1156 are shown.

1157 **(K)** Normalized change in GRAB<sub>NE1h</sub> fluorescence in response to bath application of the  
1158 indicated noradrenergic agonists in the presence or absence of ICI 118,551 or yohimbine.

1159 The scale bar shown in **(B)** represents 20  $\mu$ m; the scale bar shown in **(I)** represents 100  
1160  $\mu$ m. The scale bar shown in **(J)** represents 10  $\mu$ m.



1161 \* $p < 0.05$  and \*\*\* $p < 0.001$ ; n.s., not significant (Student's  $t$ -test, Wilcoxon test, or Mann-  
1162 Whitney rank sum test).

1163



1164

**Fig 1**




**A. Selection of NE sensitive GPCR**



**B. Insertion sites screening**



**C. Optimization of coupling linkers**



**D. Affinity tuning of NE sensors**










Fig 2


**A** Photolysis




**B** On kinetics




**C**




**D** Rapid perfusion




**E** On kinetics




**F**




**G**




**H**




**I**




**J**



**K** Tango Assay



**L** Luciferase Complement. Assay



**M** PTX treatment

















Fig 3



**Fig 4**




Fig 5





Fig 6



**Fig 7**




Fig S1




Fig S2




Fig S3

